Immunomodulatory agents, compositions and methods of use thereof

Small molecule inhibitors targeting PD-L1/PD-1 interactions address the limitations of monoclonal antibodies by enhancing cancer treatment efficacy and administration, offering improved stability, solubility, and bioavailability.

JP7579789B2Active Publication Date: 2024-11-08BETTA PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021544817
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-04
Filing Date
2020-01-20
Publication Date
2024-11-08
Estimated Expiration
2040-01-20

AI Technical Summary

Technical Problem

Current cancer treatments using monoclonal antibodies for PD-1/PD-L1 interactions face limitations such as limited tissue penetration, long half-life, lack of oral bioavailability, immunogenicity, and high production costs, necessitating the development of more potent and easily administered small molecule inhibitors.

Method used

Development of small molecule compounds that inhibit PD-L1/PD-1 interactions, characterized by specific structural formulas, which enhance immunity against cancer and infectious diseases, offering improved stability, solubility, bioavailability, and therapeutic index.

Benefits of technology

These compounds effectively inhibit PD-L1/PD-1 interactions, potentially providing more effective cancer treatment options with enhanced therapeutic efficacy and improved administration characteristics compared to monoclonal antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579789000001
    Figure 0007579789000001
  • Figure 0007579789000002
    Figure 0007579789000002
  • Figure 0007579789000003
    Figure 0007579789000003
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions containing the compounds, which are useful in the treatment, prevention, or amelioration of diseases or disorders such as cancer or infectious diseases. TIFF2022518860000226.tif51170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compounds that are inhibitors of the PD-1 / PD-L1 protein / protein interaction. The invention also relates to pharmaceutical compositions containing the compounds, as well as methods of using the compounds to treat cancer, pre-cancerous syndromes, and other diseases associated with inhibition of the PD-1 / PD-L1 protein / protein interaction. [Background technology]

[0002] Cancer immunotherapy has been increasingly utilized for the treatment of advanced malignancies. Immune checkpoint signaling networks have attracted considerable attention. Several cancers are highly refractory to conventional chemotherapy. Tumor survival in some cases is aided by immune regulatory checkpoints that maintain an imbalance between immune surveillance and cancer cell proliferation. Immune checkpoint inhibitors are revolutionizing the treatment options and expectations of cancer patients.

[0003] Programmed cell death-1 (PD-1), also known as CD279, is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and phagocytes. PD-1 functions as an intrinsic negative feedback system, preventing T cell activation, which in turn reduces autoimmunity and promotes self-tolerance. In addition, PD1 is known to play an important role in suppressing antigen-specific T cell responses in diseases such as cancer and viral infections. The interaction of PD-1 with PD-L1 reduces tumor-infiltrating lymphocytes, reduces T cell receptor-mediated proliferation, and causes immune evasion by cancer cells. Immune suppression can be reversed by blocking the local interaction of PD-1 with PDL1, and there is an additive effect when the interaction of PD-1 with PD-L2 is also blocked.

[0004] To enhance or "rescue" T cell responses, therapeutic approaches are being developed to block PD-1-mediated inhibitory signaling cascades. Most of the currently approved drugs in immunotherapy are monoclonal antibodies. These monoclonal antibodies have shown impressive clinical results in the treatment of several types of tumors. However, therapeutic antibodies have shown several drawbacks, such as limited tissue and tumor penetration, very long half-life, oral bioavailability, lack of immunogenicity, and difficult and expensive production.

[0005] In recent years, patent documents such as WO2015 / 033299 (Patent Document 1), WO2015 / 033301 (Patent Document 2), WO2015 / 034820 (Patent Document 3), WO2018 / 183171 (Patent Document 4), WO2018 / 119224 (Patent Document 5), and WO2018 / 119266 (Patent Document 6) have described that small molecules bind to PD-L1. Moreover, small molecule inhibitors that directly target PD-1 or PD-L1 have not yet been approved.

[0006] Thus, there remains a need for more potent and more easily administered therapeutics against PD-1 / PD-L1 protein / protein interactions. In the present invention, Applicants have discovered small molecules that may be active as inhibitors of the interaction between PD-L1 and PD-1, and would then be useful for therapeutic administration to enhance immunity against cancer and / or infectious diseases. These small molecules have desirable stability, solubility, bioavailability, therapeutic index and toxicity, and are expected to be useful as important agents to become efficient medicines to promote human health. Summary of the Invention

[0007] The present invention relates to compounds for use as inhibitors of the functional interaction between PD-L1 and PD-1. Inhibitors of the interaction between PD-L1 and PD-1 are useful in the treatment of cancer and infectious diseases.

[0008] The compounds of the present invention have the structure of general formula (I):

[0009] A compound of formula (I) or a stereoisomer, tautomer, pharma- ceutically acceptable salt, prodrug, chelate, non-covalent complex thereof, or solvate And, [ka] wherein R1 and R2 are each independently selected from halogen, CN, C1-6 alkyl, or C1-4 haloalkyl; Q is a -NH- or -(CH2)mO- bond; Ring A is a C5-6 aryl, a C5-6 heteroaryl, a C4-6 cycloalkyl, or a C4-6 heterocycloalkyl, and the C5-6 heteroaryl and C4-6 heterocycloalkyl are R is 1, 2 or 3 heteroatoms independently selected from N, S, or O; Including ,or, Ring A is a C8-10 fused bicyclic ring; R3 is H, halogen, -(CH2) s -NR4R5, C1-4 alkyl, C1-4 alkoxyl, hydroxyl, oxo, CN, (CH2) q -CONR4R5, -COR4, -NR4R5, -NR4C(=O)NR4R5, -NR4C(=NR4)NR4R5, -S(O)2R4, -S(O)2NR4R5, -S(O)R4, -S(O)NR4R5, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6 cycloalkyl, or C3-6 heterocycloalkyl, C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6 cycloalkyl, and C3-6 heterocycloalkyl are optionally substituted with one or more independently selected R6 substituents; R4 and R5 are each independently selected from H, C1-4 alkyl, or C3-6 cycloalkyl, C3-6 heterocycloalkyl, optionally substituted with one or more independently selected R6 substituents; or R 4 and R 5 may, together with the atoms to which they are attached, form a 4-10 membered heterocycle optionally substituted with one or more independently selected substituents, R6 substituents; R6 is H, halogen, hydroxy, oxo, CN, -(CH2) k -NR7R8, -COR7, -NR7R8, -NR7C(=O)NR7R8, -NR7C(=NR7)NR7R8, -S(O)2R7, -S(O)2NR7R8, -S(O)R7, -S(O)NR7R8, or R6 is selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocycle, wherein said C5-6 heteroaryl and C3-10 heterocycle may contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; R7 and R8 are each independently selected from H, halogen, hydroxy, oxo, CN, -S(O)2-C1-4 alkyl, -NH2, -NHC1-4 alkyl, -(CH2)-N(C1-4 alkyl)2, or R7 and R8 are each independently selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 Alkynyl , C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6 cycloalkyl, C3-6 heterocycloalkyl, wherein said C5-6 heteroaryl and C3-6 heterocycloalkyl may contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; Each of m, n, q, k and s is independently selected from 0, 1, 2, 3 or 4.

[0010] In some embodiments of Formula (I), R3 is H, halogen, -(CH2) s-NR4R5, C1-4 alkyl, C1-4 alkoxyl, hydroxyl, oxo, CN, (CH2) q -CONR4R5, -NR4R5, -NR4C(=NR4)NR4R5, -S(O)2R4, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, or C3-6 heterocycloalkyl, where C3-6 heterocycloalkyl may contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C3-6 heterocycloalkyl may be substituted with one or more independently selected R6 substituents.

[0011] In some embodiments of Formula (I), R3 is H, halogen, -(CH2) s -NR4R5, -CN, S(O)2R4, C1-4 alkyl, C1-4 alkoxyl, -(CH2) s -NR4R5, C1-4 alkyl, C1-4 alkoxyl may be optionally substituted with one or more independently selected R6 substituents.

[0012] In some embodiments of Formula (I), R6 is H, halogen, hydroxy, oxo, CN, -(CH2)k-NR7R8, -COR7, -NR7R8, -NR7C(=O)NR7R8, -S(O)2R7, or R6 is substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3~10 heterocycle, wherein said C5-6 heteroaryl and C3-10 heterocycle may contain 1, 2 or 3 heteroatoms independently selected from N, S, or O.

[0013] In some embodiments of Formula (I), R6 is H, halogen, hydroxy, oxo, CN, -(CH2)-N-(C1-4 alkyl)2, -(CH2)-NH2, -N-(C1-4 alkyl)2, -NH2, -CO-N-(C1-4 alkyl)2, -CO-NH2, -S(O)2-C1-4 alkyl, C1-4 alkyl-OH, C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocycle, wherein the C5-6 heteroaryl and C3-10 heterocycle may contain 1, 2 or 3 heteroatoms independently selected from N, S, or O.

[0014] In some Formula (I) embodiments, R6 is halogen, oxo, -OH, -NH2, -N(CH3)2, -C1-4alkylOH, -C1-4alkyl-NH-CH3, -NH-C1-4alkyl, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, C5-6aryl, C5-6heteroaryl, C3-6heterocyclyl, guanidine, or sulfone.

[0015] In some embodiments of Formula (I), R1 and R2 are each independently selected from halogen, CN, -C1-6 alkyl, or -C1-4 haloalkyl; Q is -NH- or -(CH2) m -O-bond; Ring A is a C5-6 aryl or C5-6 heteroaryl ring, which may contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; or Ring A is a C8-10 fused bicyclic ring; R3 is H, halogen, -(CH2)s-NR4R5, -C1-4 alkyl, -C1-4 alkoxyl, -(CH2) s -NR4R5, -C1~4 alkyl, -C1~4 alkoxyl are halogen, -C1~4 alkyl, -C1~4 haloalkyl, -C1~4 alkoxyl, -C5~6 heteroaryl, -C5~6 of Aryl , optionally substituted with one or more substituents independently selected from carboxyl, amino, hydroxyl, and guanidine; R4 and R5 are each independently selected from H, -C1-4 alkyl, -C3-6 cycloalkyl, -C3-6 heterocyclyl, where -C1-4 alkyl, -C3-6 cycloalkyl, -C3-6 heterocyclyl are optionally substituted with -OH, -N(CH3)2, -C1-4 alkyl, -C1-4 haloalkyl, -C3-6 heterocyclyl, -NH-C1-4 alkyl; or R 4 and R 5 form a 4- to 6-membered heterocyclic ring together with the atoms to which they are attached, optionally substituted with one or more substituents independently selected from: -OH, -N(CH3)2, -NH2, oxo, halogen, -C1-4 alkyl, -C1-4 alkoxyl, -C1-4 alkyl-OH, -C1-4 alkyl-NH-CH3; m, n, and s are each independently selected from 0, 1, 2, 3, or 4.

[0016] In some embodiments of Formula (I), Q is selected from a -NH-, or a -CH2-O- bond.

[0017] In some embodiments of Formula (I), ring A is Selected from TIFF0007579789000002.tif57170.

[0018] In some embodiments of Formula (I), ring A is Selected from TIFF0007579789000003.tif39170.

[0019] In some embodiments of Formula (I), ring A is Selected from TIFF0007579789000004.tif25170.

[0020] In some embodiments, the compound is represented by the following general formula (II): solvate And, [ka] wherein Ring B is a C5-6 cycloalkyl or a C5-6 heterocycloalkyl; R1, R2, R3 and subscript n are as defined in any embodiment of formula (I).

[0021] In some embodiments, the compound is represented by the following general formula (III): solvate And, [ka] wherein Ring C is phenyl or heteroaryl, where heteroaryl contains 1, 2 or 3 N; R1, R2, R3 and subscript n are as defined in any embodiment of formula (I).

[0022] In some embodiments, the compound is represented by the following general formula (IV): solvate And, [ka] wherein ring D is a C5-6 aryl, a C5-6 heteroaryl, or a C 5~6 Heterocycloalkyl of C5-6 heteroaryl and C 5-6 The heterocycloalkyl may contain 1, 2, or 3 heteroatoms independently selected from N, S, or O; R1, R2, R3 and subscript n are as defined in any embodiment of formula (I).

[0023] In some embodiments, the compound is represented by the following general formula (V): solvate And, [ka] R1, R2, R3 and subscript n are as defined in any embodiment of formula (I).

[0024] In some embodiments, the compound is represented by the following general formula (VI): solvate And [ka] wherein rings A, Q, R1, R2, R3 and subscript n are as defined in any embodiment of formula (I).

[0025] In some embodiments, R 1 is selected from F, Cl, —CH 3 , —CN, or —O—CH 3 .

[0026] In some embodiments, R1 is selected from -CH3, F, or -O-CH3.

[0027] In some embodiments, R2 is selected from -CH3, F, Cl, or Br.

[0028] In some embodiments, R2 is -CH3.

[0029] In some embodiments, R3 is H, F, Cl, -CH3, -CF3, -O-CF3, -O-CHF2, -O-CH3, -CN, -NH2, Selected from TIFF0007579789000010.tif219170.

[0030] In some embodiments, n is 1, 2, or 3.

[0031] In some embodiments, m is 1.

[0032] In some embodiments, s is 1.

[0033] In some embodiments, q is 1.

[0034] In some embodiments, k is 1.

[0035] In some embodiments of Formula (I), the compound is:

[0036] 1) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0037] 2) (2'S)-(((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-2,5-diyl))bis(methylene))di-L-proline

[0038] 3) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0039] 4) ((2-(2′-cyano-3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0040] 5) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0041] 6) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2′-fluoro-2-methyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0042] 7) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((2-hydroxyethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0043] 8) ((2-(3′-(5-(azetidin-1-ylmethyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0044] 9) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-fluoroazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0045] 10) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-fluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0046] 11) ((2-(3′-(5-(((S)-2-carbamoylpyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0047] 12) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0048] 13) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(morpholinomethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0049] 14) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-hydroxypyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0050] 15) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((methylamino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0051] 16) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((dimethylamino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0052] 17) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((2-hydroxyethyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0053] 18) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((3R,4R)-3,4-difluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0054] 19) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0055] 20) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-hydroxyazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0056] 21) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((ethylamino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0057] 22) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((3,3,3-trifluoro-2-hydroxypropyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0058] 23) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3,4-dimethylpiperazin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0059] 24) ((2-(3′-(5-(aminomethyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0060] 25) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0061] 26) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0062] 27) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1S,2R)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0063] 28) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((oxetan-3-ylamino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0064] 29) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((((R)-tetrahydrofuran-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0065] 30) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((methyl(((R)-tetrahydrofuran-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0066] 31) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0067] 32) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((2-(methylsulfonyl)ethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0068] 33) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-(dimethylamino)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0069] 34) ((6-(difluoromethoxy)-2-((3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0070] 35) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((R)-2-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0071] 36) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0072] 37) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2-hydroxy-2-methylazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0073] 38) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2-methylpyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0074] 39) ((2-(3′-(5-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0075] 40) ((2-(3′-(5-(2-amino-2-methylazetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0076] 41) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-(methylsulfonyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0077] 42) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((R)-2-ethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0078] 43) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-methoxyazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0079] 44) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-hydroxy-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0080] 45) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-((methylamino)methyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0081] 46) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-oxoazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0082] 47) ((2-(3′-(5-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0083] 48) ((2-(3′-(5-((2-azaspiro[3.3]heptan-2-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0084] 49) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0085] 50) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0086] 51) ((2-(3′-(5-((2,7-diazaspiro[3.5]nonan-2-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0087] 52) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((3-(propylamino)propyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0088] 53) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((methyl(3-(propylamino)propyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0089] 54) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2,2-dioxido-2-thia-6-azaspiro[3.3]heptan-6-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0090] 55) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0091] 56) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0092] 57) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2R)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0093] 58) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((3-((2-hydroxyethyl)amino)propyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0094] 59) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0095] 60) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0096] 61) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0097] 62) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2,2-dimethylpyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0098] 63) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxymethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0099] 64) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((S)-tetrahydrofuran-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0100] 65) ((2-(2′-cyano-3′-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0101] 66) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0102] 67) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3,3-dimethylpyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0103] 68) ((2-(3′-(5-((3-(diethylamino)azetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0104] 69) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-(2-hydroxypropan-2-yl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0105] 70) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((2,5-dihydro-1H-pyrrol-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0106] 71) ((2-(3′-(5-((2-azabicyclo[2.1.1]hexan-2-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0107] 72) ((2-(3′-(5-(((1s,4s)-7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0108] 73) ((2-(3′-(5-((((3,3-difluoro-1-(hydroxymethyl)cyclobutyl)methyl)amino)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0109] 74) ((2-(3′-(5-((5-azaspiro[2.3]hexan-5-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0110] 75) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-oxo-6-azabicyclo[3.2.1]octan-6-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0111] 76) ((2-(3′-(5-((1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0112] 77) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0113] 78) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-(hydroxymethyl)-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0114] 79) ((2-(3′-(5-((3-cyano-3-methylazetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0115] 80) ((2-(3′-(5-((3-cyanoazetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0116] 81) ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3-methyleneazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0117] 82) ((2-(3′-(5-((3-(cyanomethylene)azetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0118] 83) ((2-(2,2′-dicyano-3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0119] 84) ((6-(difluoromethoxy)-2-(3′-(5-((3,4-dimethylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0120] 85) (R)-1-((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0121] 86) (S)-1-((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0122] 87) ((2-(2′-cyano-3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0123] 88) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0124] 89) ((2-(3′-(5-((2-azabicyclo[2.1.1]hexan-2-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0125] 90) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0126] 91) (3R)-1-((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0127] 92) (3S)-1-((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0128] 93) ((6-(difluoromethoxy)-2-((3′-(5-(3,3-dimethylazetidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0129] 94) ((2-(3′-(5-(azetidin-1-ylmethyl)-7-methylbenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0130] 95) ((6-(difluoromethoxy)-2-(3′-(7-fluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0131] 96) ((6-(difluoromethoxy)-2-(3′-(5-(ethylamino)methyl)-6-fluorobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0132] 97) ((2-(3′-(6-chloro-5-((ethylamino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0133] 98) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0134] 99) ((6-(difluoromethoxy)-2-(3′-(5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0135] 100) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0136] 101) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0137] 102) ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0138] 103) ((2-(3′-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0139] 104) ((6-(difluoromethoxy)-2-(3′-(5-((2-hydroxy-2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0140] 105) ((6-(difluoromethoxy)-2-(3′-(5-((2-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0141] 106) ((2-(3′-(5-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0142] 107) ((2-(3′-(5-((1-azaspiro[3.3]heptan-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0143] 108) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0144] 109) ((6-(difluoromethoxy)-2-(3′-(6-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0145] 110) ((2-(2′-chloro-3′-(6-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0146] 111) ((2-(2′-chloro-3′-(6-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0147] 112) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)oxazolo[5,4-b]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0148] 113) ((6-(difluoromethoxy)-2-(3′-(6-((3,3-dimethylazetidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0149] 114) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(((R)-3-methylpyrrolidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0150] 115) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)oxazolo[5,4-b]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0151] 116) ((6-(difluoromethoxy)-2-(3′-(6-((3-(dimethylamino)azetidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0152] 117) ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2′-methoxy-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0153] 118) ((2-(2′-cyano-3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0154] 119) ((2-(3′-(6-((6-cyanopyridin-3-yl)methoxy)-5-(((2-hydroxyethyl)methyl)amino)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0155] 120) ((2-(3′-(6-((5-cyanopyridin-3-yl)methoxy)-5-(((2-hydroxyethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0156] 121) ((6-(difluoromethoxy)-2-(3′-(5-(((2-hydroxyethyl)amino)methyl)-6-((5-(methylsulfonyl)pyridin-3-yl)methoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0157] 122) ((6-(difluoromethoxy)-2-(3′-(5-((ethylamino)methyl)-6-((5-(methylsulfonyl)pyridin-3-yl)methoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0158] 123) ((6-(difluoromethoxy)-2-(3′-(5-((dimethylamino)methyl)-6-((5-(methylsulfonyl)pyridin-3-yl)methoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0159] 124) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(methylamino)methyl)-6-((3-(methylsulfonyl)benzyl)oxy)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0160] 125) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((methylamino)methyl)-6-((4-(methylsulfonyl)benzyl)oxy)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0161] 126) ((6-(difluoromethoxy)-2-(3′-(5-((dimethylamino)methyl)-6-((4-(methylsulfonyl)benzyl)oxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0162] 127) ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0163] 128) ((2-(2-cyano-3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2′-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0164] 129) ((2-(3′-(7-cyano-5-((3-(hydroxymethyl)-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0165] 130) ((2-(3′-(7-cyano-5-(((S)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0166] 131) ((2-(3′-(7-cyano-5-(((R)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0167] 132) ((2-(3′-(7-cyano-5-(((R)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0168] 133) ((2-(3′-(7-cyano-5-(((3-methyloxetan-3-yl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0169] 134) ((2-(3′-(7-cyano-5-((3-(dimethylamino)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0170] 135) ((2-(3′-(7-cyano-5-((2-(2-hydroxyethyl)piperidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0171] 136) ((2-(3′-(7-cyano-5-(((cyanomethyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0172] 137) ((2-(3′-(7-cyano-5-((3-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0173] 138) ((2-(3′-(7-cyano-5-(((2-hydroxy-2-methylpropyl)amino)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0174] 139) ((2-(3′-(7-cyano-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0175] 140) ((2-(3′-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0176] 141) ((2-(3′-(7-cyano-5-((ethyl(2-hydroxyethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0177] 142) ((2-(3′-(7-cyano-5-((3-cyanopyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0178] 143) ((2-(3′-(7-cyano-5-((3-cyanopyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0179] 144) ((2-(3′-(7-cyano-5-((3-ethynyl-3-hydroxyazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0180] 145) ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0181] 146) ((2-(3′-(7-cyano-5-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0182] 147) ((2-(3′-(5-((bis(1-hydroxypropan-2-yl)amino)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0183] 148) ((2-(3′-(7-cyano-5-((3-morpholinoazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0184] 149) ((2-(3′-(7-cyano-5-((3-(methyl(oxetan-3-yl)amino)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0185] 150) ((2-(3′-(7-cyano-5-((3-hydroxy-3-methyl-[1,3′-biazetidin]-1′-yl)methyl))benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0186] 151) ((2-(3′-(7-cyano-5-((6-oxo-2,5-diazaspiro[3.4]octan-2-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0187] 152) ((2-(3′-(7-cyano-5-((3-((dimethylamino)methyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0188] 153) ((2-(3′-(7-cyano-5-((1,1-difluoro-5-azaspiro[2.4]heptan-5-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0189] 154) ((2-(3′-(7-cyano-5-(((R)-3-(hydroxymethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0190] 155) ((2-(3′-(7-cyano-5-(((3-hydroxycyclobutyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0191] 156) ((2-(3′-(5-((3-amino-4-methylpyrrolidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0192] 157) ((2-(3′-(5-(((azetidin-3-ylmethyl)amino)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0193] 158) ((2-(3′-(7-cyano-5-((3-(dimethylamino)-4-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0194] 159) ((2-(3′-(7-cyano-5-((3-(dimethylamino)methyl)-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0195] 160) ((2-(3′-(7-cyano-5-((((1-methyl-1H-imidazol-4-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0196] 161) ((2-(3′-(5-((3-(aminomethyl)-3-methylazetidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0197] 162) ((2-(3′-(7-cyano-5-((3-fluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0198] 163) ((2-(3′-(7-cyano-5-((3-fluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0199] 164) ((2-(3′-(7-cyano-5-((3,4-difluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0200] 165) ((2-(3′-(7-cyano-5-(((R)-3-cyanopyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0201] 166) ((6-(difluoromethoxy)-2-(3′-(5-((3-fluoropyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0202] 167) ((2-(3′-(7-cyano-5-((3-fluoro-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0203] 168) ((2-(3′-(7-cyano-5-(((R)-3-(fluoromethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0204] 169) (R)-1-((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0205] 170) ((6-(difluoromethoxy)-2-(3′-(6-((3,3-dimethylazetidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0206] 171) (S)-1-((8-((3′-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)-2-methylpyrrolidine-2-carboxylic acid;

[0207] 172) ((2-(3′-((3-(((carboxymethyl)amino)methyl)-1,7-naphthyridine-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0208] 173) (S)-1-((8-((3′-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)piperidine-2-carboxylic acid;

[0209] 174) ((6-(difluoromethoxy)-2-(3′-((3-((3-fluoropyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0210] 175) ((6-(difluoromethoxy)-2-(3′-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0211] 176) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((3-(morpholinomethyl)-1,7-naphthyridine-8-yl)amino)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0212] 177) ((2-(3′-((3-(azetidin-1-ylmethyl)-1,7-naphthyridine-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0213] 178) ((6-(difluoromethoxy)-2-(3′-((3-((3-hydroxyazetidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0214] 179) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((3-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-1,7-naphthyridin-8-yl)amino)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0215] 180)(3S)-1-((6-(difluoromethoxy)-2-(3′-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridine-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0216] 181)(3R)-1-((6-(difluoromethoxy)-2-(3′-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridine-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0217] 182) ((6-(difluoromethoxy)-2-(3′-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0218] 183) ((5-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)amino)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-6-yl)methyl)-L-proline;

[0219] 184) ((2-(3′-(5-(carboxymethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0220] 185) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(2-(methylsulfonyl)ethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0221] 186) ((2-(3′-(5-(1-carboxyethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0222] 187) ((2-(3′-(5-(2-carboxyethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0223] 188) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0224] 189) ((6-(difluoromethoxy)-2-(3′-(5-(2-hydroxyethyl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0225] 190) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0226] 191) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0227] 192) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(oxetan-2-ylmethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0228] 193) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0229] 194) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0230] 195) ((2-(3′-(5-(cyanomethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0231] 196) ((2-(3′-(5-(2-amino-2-oxoethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0232] 197) ((6-(difluoromethoxy)-2-(3′-(5-(ethylsulfonyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0233] 198) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0234] 199) ((6-(difluoromethoxy)-2-(3′-(5-(3-hydroxypropyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0235] 200) ((6-(difluoromethoxy)-2-(3′-(5-(3-fluoropropyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0236] 201) ((2-(3′-(5-(2,2-difluoroethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0237] 202) ((6-(difluoromethoxy)-2-(3′-(5,6-dihydro-4H-pyrrolo[3,4-d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0238] 203) ((6-(difluoromethoxy)-2-(3′-(6,7-dihydro-4H-pyrano[3,4-d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0239] 204) ((6-(difluoromethoxy)-2-(3′-(5,6-dihydro-4H-cyclopenta[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0240] 205) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrobenzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0241] 206) ((6-(difluoromethoxy)-2-(3′-(5-(2-hydroxyethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0242] 207) 2-((2-(2′-cyano-2-methyl-3′-(4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)pyrrolidine-1-carboxylic acid;

[0243] 208) ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0244] 209) ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-((3-fluoropyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0245] 210) ((2-(3′-((4-(((2-acetamidoethyl)amino)methyl)-2-chloro-5-((3-cyanobenzyl)oxy)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0246] 211) ((2-(3′-((4-(((S)-2-carboxypyrrolidin-1-yl)methyl)-2-chloro-5-((3-cyanobenzyl)oxy)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0247] 212) ((6-(difluoromethoxy)-2-(3′-(((4,6-dimethoxy-5-(pyrrolidin-1-ylmethyl)pyrimidin-2-yl)oxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0248] 213) ((6-(difluoromethoxy)-2-(3′-(((5-((3,3-dimethylazetidin-1-yl)methyl)-4,6-dimethoxypyrimidin-2-yl)oxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0249] 214) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyridin-2-yl)oxy)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0250] 215) ((6-(difluoromethoxy)-2-(2′-fluoro-2-methyl-4″″-((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1′:3′,1″″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0251] 216) ((6-(difluoromethoxy)-2-(3″″-(difluoromethoxy)-2′-fluoro-2-methyl-4″″-((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1′:3′:1″″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0252] 217) ((6-(difluoromethoxy)-2-(4″″-(((2-hydroxyethyl)amino)methyl)-2,2′-dimethyl-[1,1′:3′,1″″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0253] 218) ((6-(difluoromethoxy)-2-(2,2′,3″-trimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0254] 219) ((2-(3″-chloro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0255] 220) ((6-(difluoromethoxy)-2-(2″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0256] 221) ((2-(2′-bromo-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0257] 222) ((2-(2′-chloro-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0258] 223) ((2-(2′-chloro-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0259] 224) ((2-(2′-chloro-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0260] 225) ((6-(difluoromethoxy)-2-(4″-guanidino-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0261] 226) ((6-(difluoromethoxy)-2-(4″-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-2,2′-dimethyl-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0262] 227) ((6-(difluoromethoxy)-2-(4″-((3-methoxypyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0263] 228) ((6-(difluoromethoxy)-2-(4″-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0264] 229) ((2-(3″-chloro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0265] 230) ((6-(difluoromethoxy)-2-(2,2′,3″-trimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0266] 231) ((2-(2″-chloro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0267] 232) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-3″-(trifluoromethoxy)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0268] 233) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-3″-(trifluoromethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0269] 234) ((6-(difluoromethoxy)-2-(2,2′,3″,5″-tetramethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0270] 235) ((6-(difluoromethoxy)-2-(3″-fluoro-5″-methoxy-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0271] 236) ((2-(3″-carboxy-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0272] 237) ((6-(difluoromethoxy)-2-(4″-((3,3-dimethylazetidin-1-yl)methyl)-3″-fluoro-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0273] 238) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-((3-methylpyrrolidin-1-yl)methyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0274] 239) ((6-(difluoromethoxy)-2-(3″-fluoro-4″-(((2-hydroxyethyl)amino)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0275] 240) ((2-(3″-cyano-4″-(((S)-3-(hydroxymethyl)pyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0276] 241) ((6-(difluoromethoxy)-2-(3″-fluoro-4″-(isoindolin-2-ylmethyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0277] 242) ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0278] 243) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0279] 244) ((6-(difluoromethoxy)-2-(3″-(difluoromethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0280] 245) ((2-(3″-cyano-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0281] 246) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0282] 247) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0283] 248) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-(((S)-3-phenylpyrrolidin-1-yl)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0284] 249) ((6-(difluoromethoxy)-2-(3″-(4-fluorophenethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline;

[0285] 250) ((2-(3″-(cyclopropylmethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0286] 251) ((2-(4″-(((R)-3-(1H-tetrazol-5-yl)pyrrolidin-1-yl)methyl)-3″-fluoro-2,2′-dimethyl-[1,1′:3′:1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0287] 252) ((2-(4″-(((S)-3-((benzyloxy)methyl)pyrrolidin-1-yl)methyl)-3″-fluoro-2,2′-dimethyl-[1,1′:3′:1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline;

[0288] 253) ((6-(difluoromethoxy)-2-(2″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0289] 254) ((6-(difluoromethoxy)-2-(3″,5″-dimethoxy-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline hydrochloride;

[0290] 255) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-4″-(pyrrolidin-2-yl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0291] 256) ((2-(4″-((S)-amino(carboxy)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0292] 257) ((6-(difluoromethoxy)-2-(4″-(((S)-3-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)pyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0293] 258) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-((5-ureidoisoindolin-2-yl)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0294] 259)(S)-1-((2-(3′-(7-cyano-5-(((S)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

[0295] 260) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-((3-ureidopyrrolidin-1-yl)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0296] 261) ((2-(3′-(5-(((S)-3-chloropyrrolidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0297] 262) ((6-(difluoromethoxy)-2-(3′-(4-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0298] 263) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0299] 264) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0300] 265) ((6-(difluoromethoxy)-2-(3′-(5-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0301] 266) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0302] 267) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-oxo-5-(pyrrolidin-1-ylmethyl)-1,6-dihydropyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0303] 268) ((6-(difluoromethoxy)-2-(2′-(difluoromethyl)-3′-(5-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2-methyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0304] 269) ((6-(difluoromethoxy)-2-(3′-(5-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2′-(fluoromethyl)-2-methyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0305] 270) ((6-(difluoromethoxy)-2-(3′-(2-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0306] 271) ((6-(difluoromethoxy)-2-(3′-(5-((3,3-dimethylazetidin-1-yl)methyl)-6-methoxypyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0307] 272) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((R)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0308] 273) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0309] 274) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-4-vinylpyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0310] 275) ((6-(difluoromethoxy)-2-(3′-(5-((3-(difluoromethyl)pyrrolidin-1-yl)methyl)-6-methoxypyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)-methyl)-L-proline;

[0311] 276) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0312] 277) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0313] 278) ((2-(3′-(5-(((1s,4s)-7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-methoxypyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0314] 279) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((R)-2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0315] 280) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)thiophen-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0316] 281) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-(pyrrolidin-1-ylmethyl)pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0317] 282) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0318] 283) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0319] 284) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)pyrazin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0320] 285) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(pyrrolidin-1-ylmethyl)pyrazin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0321] 286) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((R)-3-methylpyrrolidin-1-yl)methyl)pyrazin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0322] 287) ((2-(2′-chloro-3′-(6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0323] 288) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(1,2,3,4-tetrahydroisoquinolin-6-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0324] 289) ((6-(difluoromethoxy)-2-(3′-(isoindolin-5-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0325] 290) ((2-(3′-(2-(2-carboxyethyl)isoindolin-5-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0326] 291) ((2-(3′-(2-(carboxymethyl)isoindolin-5-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0327] 292) ((2-(3′-(2-(1-carboxyethyl)isoindolin-5-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0328] 293) ((2-(3′-(2-amino-1H-benzo[d]imidazol-5-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0329] 294) ((6-(difluoromethoxy)-2-(3′-(5-((3,3-dimethylpyrrolidin-1-yl)methyl)-6-methoxypyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0330] 295) ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0331] 296) ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0332] 297) ((6-(difluoromethoxy)-2-(3′-(6-fluoro-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0333] 298) ((2-(3′-(6,7-difluoro-1-methyl-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0334] 299) ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0335] 300) ((2-(3′-(4,5-difluoro-6-(pyrrolidin-1-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0336] 301) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0337] 302) ((2-(2′-chloro-3′-(5-(((2-hydroxyethyl)amino)methyl)picolinamido)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0338] 303) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamido)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0339] 304) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-methyl-5-(pyrrolidin-1-ylmethyl)oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0340] 305) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0341] 306) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-(pyrrolidin-1-yl)piperidin-1-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0342] 307) ((6-(difluoromethoxy)-2-(3′-(4-(((1-(hydroxymethyl)cyclopropyl)methyl)amino)piperidin-1-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0343] 308) ((6-(difluoromethoxy)-2-(3′-(4-((3,3-dimethylazetidin-1-yl)methyl)piperidin-1-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0344] 309) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-(pyrrolidin-1-ylmethyl)piperidin-1-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0345] 310) ((6-(difluoromethoxy)-2-(3′-(5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline;

[0346] 311) ((6-(difluoromethoxy)-2-(3′-(5-((2,2-dimethylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0347] 312) ((6-(difluoromethoxy)-2-(3′-(5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0348] 313) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0349] 314) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0350] 315) ((2-(3′-(5-((3-carbamoylpyrrolidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline;

[0351] 316) ((2-(3′-(7-cyano-5-((3-cyano-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline).

[0352] The present invention also provides a pharmaceutical composition comprising any of the compounds of the present invention and a pharma- ceutically acceptable excipient, such as hydroxypropylmethylcellulose, in which the weight ratio of the compound to the excipient is in the range of about 0.0001-10.

[0353] The present invention further provides the use of a pharmaceutical composition of formula I for the preparation of a medicament for treating a disease in a subject. The present invention further provides some preferred technical solutions for the above uses.

[0354] In some embodiments, the medicament thus prepared can be used to treat or prevent cancer, cancer metastasis, immune disorders, or to delay the onset or progression of cancer, cancer metastasis, immunological disorders, wherein the cancer is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, kidney cancer, prostate cancer, ovarian cancer, or breast cancer.

[0355] The invention provides a method of inhibiting PD-1 / PD-L1 interaction, the method comprising administering to a patient a compound, or a pharma- ceutically acceptable salt or stereoisomer thereof, per se.

[0356] The present invention provides a method for treating a disease associated with inhibition of PD-1 / PD-L1 interaction, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt or stereoisomer thereof, wherein the disease is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.

[0357] The present invention provides a method of enhancing, stimulating and / or increasing an immune response in a patient, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt or stereoisomer thereof, per se. The present invention also provides the use of a compound of the present invention, or a pharmaceutical composition thereof, for the preparation of a medicament. In some embodiments, the medicament is used for the treatment or prevention of cancer.

[0358] In some embodiments, the cancer is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer, or breast cancer.

[0359] In some embodiments, the agent is used as an inhibitor of the PD-1 / PD-L1 interaction.

[0360] In some embodiments, the medicaments are used to enhance, stimulate and / or increase an immune response in a patient.

[0361] General chemical terms used in the above formulas have their usual meanings. For example, the term "halogen" as used herein means fluoro, chloro, bromo or iodo unless otherwise indicated. Preferred halogen groups include F, Cl and Br.

[0362] As used herein, unless otherwise indicated, alkyl includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties. For example, alkyl groups include methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-hexyl, 2-methylpentyl, and cyclohexyl. Similarly, C, as in C alkyl, includes C 1-4 alkyl. 1-4 is defined to identify a group having 1, 2, 3, or 4 carbon atoms arranged in a straight or branched chain.

[0363] Alkenyl and alkynyl groups include straight chain, branched or cyclic alkenyl and alkynyl. Similarly, "C2-8 alkenyl" and "C2-8 alkynyl" refer to alkenyl or alkynyl groups having 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or vicinal arrangement.

[0364] Alkoxy groups are ether oxygens formed from the previously described straight, branched or cyclic alkyl groups.

[0365] The term "aryl" as used herein, unless otherwise indicated, refers to an unsubstituted or substituted monocyclic or polycyclic ring system containing cyclic carbon atoms. Preferably, aryl is a monocyclic or bicyclic 6-10 membered aromatic ring system. Preferably, aryl is phenyl and naphthyl. Most preferably, aryl is phenyl.

[0366] The term "heterocyclyl," as used herein, unless otherwise indicated, refers to an unsubstituted or substituted stable 3- to 10-membered saturated or partially unsaturated monocyclic, spirocyclic, bridged bicyclic or fused bicyclic ring system, which ring system consists of carbon atoms and from 1 to 3 heteroatoms selected from N, O or S, wherein the nitrogen or sulfur heteroatom may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heterocyclyl group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure. Examples of such heterocyclyl groups include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl.

[0367] The term "heteroaryl," as used herein, unless otherwise indicated, refers to an unsubstituted or substituted stable 5- or 6-membered monocyclic aromatic ring system, or an unsubstituted or substituted 9- or 10-membered benzo-fused heteroaromatic ring system, or a bicyclic aromatic ring system, which consists of carbon atoms and from 1 to 3 heteroatoms selected from N, O or S, wherein the nitrogen or sulfur heteroatom may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroaryl group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure. Examples of heteroaryl groups include, but are not limited to, thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzodisooxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotridiazolyl, benzotriazolyladenine, quinolinyl, or isoquinolinyl.

[0368] The term "alkenyloxy" refers to the group --O-alkenyl, where alkenyl is defined above.

[0369] The term "alkynyloxy" refers to the group --O-alkynyl, where alkynyl is defined above.

[0370] The term "cycloalkyl" refers to a cyclic saturated alkyl chain having from 3 to 12 carbon atoms, such as, for example, cyclopropyl, cyclobutyl, cyclobutyl, cyclobutyl.

[0371] The term "substituted" refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituents. Exemplary substituents include halogen (F, Cl, Br, or I), C 1-8 Alkyl, C 3-12 Cycloalkyl, -OR 1 , S.R. 1 , =O, =S, -C(O)R 1 , -C(S)R 1 , =NR 1 , -C(O)OR 1 , -C(S)OR 1 , -NR 1 R 2 , -C(O)NR 1 R 2 , cyano, nitro, -S(O)2R 1 , -OS(O)2OR 1 , -OS(O)2R 1 , -OP(O)(OR 1 )(OR 2 ) but are not limited thereto; 1 and R 2is independently selected from -H, lower alkyl, lower haloalkyl. In some embodiments, the substituents are independently selected from the group consisting of -F, -Cl, -Br, -I, -OH, trifluoromethoxy, ethoxy, propyloxy, iso-propyloxy, n-butyloxy, isobutyloxy, t-butyloxy, -SCH3, -SC2H5, a formaldehyde group, -C(OCH3), cyano, nitro, CF3, -OCF3, amino, dimethylamino, methylthio, sulfonyl, and acetyl.

[0372] The term "composition" as used herein is intended to include any product that contains the specified amount of the specified ingredients, as well as any product that results directly or indirectly from the combination of the specified amounts of the specified ingredients. Thus, pharmaceutical compositions containing the compounds of the present invention as active ingredients, as well as methods for preparing the compounds, are also part of the present invention. It should be noted that some of the crystalline forms of the compounds may be polymorphic, and as such, are intended to be included in the present invention. Furthermore, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be included within the scope of the present invention.

[0373] Examples of substituted alkyl groups include, but are not limited to, 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, methoxymethyl, pentafluoroethyl, and piperazinylmethyl.

[0374] Examples of substituted alkoxy groups include, but are not limited to, aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, and 3-hydroxypropoxy.

[0375] The compounds of the present invention may be in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of the present invention refer to non-toxic "pharmaceutically acceptable salts". Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic / anionic or basic / cationic salts. The pharmaceutically acceptable acidic / anionic salts are generally in the form in which the basic nitrogen is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, perchloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, lactic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, hydroxyethanesulfonic acid, benzenesulfonic acid, oxalic acid, pamoic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, cyclohexanesulfamine, salicylic acid, saccharic acid or trifluoroacetic acid. Pharmaceutically acceptable basic / cationic salts include, but are not limited to, aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.

[0376] The present invention includes within its scope prodrugs of the compounds of the present invention. In general, such prodrugs are functional derivatives of the compounds that are easily converted in vivo to the required compound. Thus, in the treatment methods of the present invention, the term "administering" is intended to encompass the treatment of the various disorders described with a compound specifically disclosed or with a compound not specifically disclosed, but which converts to a particular compound in vivo after administration to a subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," edited by H. Bundgaard, Elsevier, 1985.

[0377] It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of the invention can be selected by those skilled in the art to provide compounds that are chemically stable and can be readily synthesized by techniques known in the art as well as the methods described herein.

[0378] The present invention includes compounds described herein that may contain one or more asymmetric centers and thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers, as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and their pharma- ceutically acceptable salts.

[0379] The above formula I is shown without stereochemical definition at specific positions. The present invention includes all stereoisomers of formula I and pharma- ceutically acceptable salts thereof. It also includes mixtures of stereoisomers as well as isolated specific stereoisomers. In the synthetic procedures used to prepare such compounds, or in racemization or epimerization procedures known to those skilled in the art, the products of such procedures may be mixtures of stereoisomers.

[0380] In cases where tautomers of the compounds of formula I exist, the present invention includes any possible tautomers and pharma- ceutically acceptable salts thereof, and mixtures thereof, unless specifically stated otherwise.

[0381] When the compound of formula I and its pharmaceutically acceptable salts exist in the form of solvate or polymorph, the present invention includes any possible solvate and polymorph.The type of the solvent that forms the solvate is not particularly limited, as long as the solvent is pharmacologically acceptable.For example, water, ethanol, propanol, acetone, etc. may be used.

[0382] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salts can be easily prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts obtained from such inorganic bases include aluminum, ammonium, calcium, copper (I and II), ferric, ferrous, lithium, magnesium, manganous (I and II), potassium, sodium, zinc, and the like salts. Particularly preferred are ammonium, calcium, magnesium, potassium, and sodium salts. Salts obtained from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthetically substituted amines. Other pharma- ceutically acceptable organic non-toxic bases with which salts can be formed include, for example, arginine, betaine, caffeine, choline, N′,N″-dibenzylethylenediamine, diethylamino, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

[0383] When the compound of the present invention is basic, its corresponding salt can be easily prepared from pharma- ceutically acceptable non-toxic acid, including inorganic and organic acids.Such acids include, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc.Citric acid, hydrobromic acid, formic acid, hydrochloric acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid are preferred, and formic acid and hydrochloric acid are particularly preferred. Since the compounds of formula I are intended for pharmaceutical use, they are preferably provided in substantially pure form, e.g. at least 60% pure, more preferably at least 75% pure, and especially preferably at least 98% pure (percentages are by weight).

[0384] The pharmaceutical compositions of the present invention comprise a compound represented by formula I (or a pharma- ceutically acceptable salt thereof) as an active ingredient, a pharma- ceutically acceptable carrier, and optionally other therapeutic ingredients or adjuvants. The compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host and the nature and severity of the condition for which the active ingredient is to be administered. The pharmaceutical compositions may be conveniently provided in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.

[0385] In practice, the compound of the present invention represented by formula I, or a prodrug, or a metabolite thereof, or a pharma- ceutically acceptable salt thereof, as an active ingredient, is intimately combined with a pharmaceutical carrier to obtain a mixture according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms, depending on the form of preparation, for example, oral or parenteral (including intravenous) administration desired. Thus, the pharmaceutical composition of the present invention can be provided as discrete units suitable for oral administration, such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient. Furthermore, the composition can be provided as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-inoyl liquid emulsion. In addition to the common dosage forms described above, the compound of the present invention represented by formula I, or a pharma- ceutically acceptable salt thereof, can also be administered by controlled release means and / or delivery devices. The composition can be prepared by any of the methods of pharmacy. In general, such methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, or finely divided solid carriers, or both, The product can then conveniently be shaped into the desired presentation.

[0386] Thus, the pharmaceutical compositions of the present invention include a pharma- ceutically acceptable carrier and a compound, or a pharma- ceutically acceptable salt, of Formula I. The compound of Formula I, or a pharma- ceutically acceptable salt thereof, can be included in the pharmaceutical composition in combination with one or more other therapeutically active compounds.

[0387] The pharmaceutical carriers used may be, for example, solid, liquid, or gaseous. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers include sugar solution, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. Any convenient pharmaceutical medium may be used in preparing compositions for oral dosage forms. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like can be used to form oral liquid preparations such as suspensions, elixirs, and solutions; while carriers such as starch, sugar, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules, and tablets. Because they are easily administered, tablets and capsules are preferred oral dosage units in which solid pharmaceutical carriers are used. If necessary, tablets can be coated by standard aqueous or nonaqueous techniques.

[0388] Tablets containing the composition of the present invention can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surfactant or dispersant. Molded tablets can be produced by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains about 0.05 mg to 5 g of the active ingredient, and each cachet or capsule preferably contains about 0.05 mg to 5 g of the active ingredient. For example, a formulation intended for oral administration to humans may contain about 0.5 mg to about 5 g of the active agent combined with an appropriate and convenient amount of carrier material, which may vary from about 5 to 95% of the total composition. A unit dosage form will generally contain from about 1 mg to 2 g of active ingredient, typically containing 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

[0389] The pharmaceutical composition of the present invention suitable for parenteral administration can be prepared as an aqueous solution or suspension of active compound.It can contain suitable surfactant such as hydroxypropylcellulose.Dispersion can also be prepared in glycerol, liquid polyethylene glycol and mixtures thereof in oil.In addition, preservatives can be included to prevent harmful growth of microorganisms.

[0390] The pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Moreover, the compositions may be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In any case, the final injectable form must be sterile and effectively fluid for easy injectability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, they must be preserved against the contamination of microorganisms such as bacteria and fungi. The carrier may be, for example, a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

[0391] The pharmaceutical composition of the present invention can be in a form suitable for topical use, such as, for example, an aerosol, cream, ointment, lotion, dusting powder, etc. Additionally, the composition can be in a form suitable for use in transdermal devices. These formulations can be prepared by conventional processing methods utilizing the compound of formula I of the present invention, or a pharma-ceutically acceptable salt thereof. As an example, a cream or ointment is prepared by mixing a hydrophilic material and water together with about 5 wt% to 10 wt% of the compound to produce a cream or ointment having the desired viscosity.

[0392] The pharmaceutical composition of the present invention may be in a form suitable for rectal administration, where the carrier is solid.Preferably, the mixture is formed into unit dose suppositories.Suitable carriers include cocoa butter and other materials commonly used in the art.The suppositories can be conveniently formed by first mixing the composition with the softened or melted carrier, followed by cooling and shaping in molds.

[0393] In addition to the carrier components, the pharmaceutical formulations described above can optionally include one or more additional carrier components such as diluents, buffers, flavorings, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants). In addition, the formulations that are isotonic with the blood of the intended recipient may include other auxiliary agents. The compositions containing the compound of formula I or its pharma- ceutically acceptable salts can also be prepared in the form of powder or liquid concentrate.

[0394] In general, dosage levels of about 0.01 mg / kg to 150 mg / kg of body weight daily are useful in treating the above conditions, or alternatively, dosages of about 0.5 mg to about 7 g per patient per day. For example, colon cancer, rectal cancer, mantle cell lymphoma, multiple myeloma, breast cancer, prostate cancer, glioblastoma, squamous cell esophageal carcinoma, liposarcoma, T-cell lymphoma melanoma, pancreatic cancer, glioblastoma or lung cancer may be effectively treated by administration of about 0.01 to 50 mg per kg of body weight daily, or alternatively about 0.5 mg to 3.5 g per patient.

[0395] However, it is understood that lower or higher doses than those listed above may be required.The specific dose level and treatment regimen for any particular subject will depend on various factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, administration time, administration route, excretion rate, drug combination, the severity and course of the specific disease being treated, the predisposition of the subject to disease, and the judgment of the treating physician. These and other aspects will become apparent from the following written description of the invention.

[0396] The following examples are provided to better illustrate the invention. All parts and percentages are by weight and all temperatures are in degrees Celsius unless otherwise stated.

[0397] The present invention will be described in more detail by specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any manner. Those skilled in the art will readily recognize a variety of non-critical parameters that can be changed or modified to produce essentially the same results. The compounds of the examples have been found to inhibit the activity of PD-1 / PD-L1 protein / protein interaction according to at least one assay described herein. EXAMPLES

[0398] The experimental procedures for the compounds of the present invention are given below. Open access LCMS preparative purification of some of the prepared compounds was carried out on Waters mass directed fractionation systems. The basic instrument setup, protocols, and control software for the operation of this system are described in detail in the literature. See, e.g., Blom, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 2002, 4, 295-301; Blom et al, "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. Combi. Chem., 2003, 5, 670-83; and Blom et al, Chemistry, 2004, 6, 874-883. al. Chem., 2004, 6, 874-883).

[0399] The compounds described herein can be obtained commercially or synthesized by conventional methods using commercially available starting materials and reagents, as shown below. The following abbreviations have been used in the examples: EA: ethyl acetate; STAB: sodium triacetoxyborohydride; TBAI: tetrabutylammonium iodide; DMF: dimethylformamide; THF: tetrahydrofuran; TEA: triethylamine; TLC: thin layer chromatography; AcOH or HOAC: acetic acid; BSA: bovine serum albumin; DCM: dichloromethane; DDQ: 2,3-dichloro-5,6-dicyano-p-benzoquinone; DMSO: dimethyl sulfoxide; EtOAc: ethyl acetate; h or hrs: plural of hour or time; HTRF: homogeneous time-resolved fluorescence; MeOH: methanol; min:minutes; PE: petroleum ether; Pd(dppf)C l2 :[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium; rt or RT: room temperature; TBAI: tetrabutylammonium iodide; THF: tetrahydrofuran; Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium; NBS: N-bromosuccinimide; BPO: benzoyl peroxide; TLC: thin layer chromatography.

[0400] Synthesis of intermediates Example A Synthesis of Intermediate A ((6-(difluoromethoxy)-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0401] [ka]

[0402] Step 1: Preparation of methyl 2,4-dihydroxy-5-nitrobenzoate

[0403] [ka]

[0404] Methyl 2,4-dihydroxybenzoate (850 g) was dissolved in a mixture of glacial AcOH (3.6 L) and Ac2O (900 ml). After cooling to 10°C (ice bath), a mixture of glacial AcOH (500 mL) and concentrated HNO3 (65%) (455 ml) was added over 1 h to the clear solution. The light brown solution was allowed to warm to 15-20°C and stirring was continued for another 1 h. The reaction was poured into H2O (3 L). The precipitate was filtered, rinsed with a small amount of H2O, and the crude product was then poured into MeOH (2 L) with stirring. The precipitate was filtered, rinsed with a small amount of MeOH, and dried under reduced pressure to give 480 g of the title product.

[0405] Step 2: Preparation of methyl 5-amino-2,4-dihydroxybenzoate

[0406] [ka]

[0407] A mixture of compound a-2 (77.1 g) and 10% Pd(OH) / C (11.5 g) in methanol (2 L) was stirred at room temperature under 1.1 atm hydrogen pressure for 3 h. The catalyst was then removed by filtration, the solid residue was washed with methanol (300 mL), and the solvent was removed under reduced pressure to obtain 72 g of methyl 5-amino-2,4-dihydroxybenzoate.

[0408] Step 3: Preparation of methyl 2-(3-bromo-2-methylphenyl)-6-hydroxybenzo[d]oxazole-5-carboxylate

[0409] [ka]

[0410] A mixture of methyl 5-amino-2,4-dihydroxybenzoate (32.9 g) and 3-bromo-2-methylbenzaldehyde (32.5 g) in MeOH (1 L) was stirred at 80° C. for 2.5 h, then the resulting mixture was concentrated under reduced pressure. DCM (500 ml) was added to the mixture, and DDQ (55.6 g) was added. The mixture was stirred at room temperature for 1 h. The reaction was diluted with DCM and washed with aqueous Na2S2O3 and aqueous NaHCO3. The organic phase was dried over MgSO4, filtered, and the filtrate was concentrated. The crude product was purified by column chromatography (PE:DCM=1 / 1) to give 45 g of methyl 2-(3-bromo-2-methylphenyl)-6-hydroxybenzo[d]oxazole-5-carboxylate as a brown solid.

[0411] Step 4: Preparation of methyl 2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carboxylate

[0412] [ka]

[0413] Methyl 2-(3-bromo-2-methylphenyl)-6-hydroxybenzo[d]oxazole-5-carboxylate (10.0 g), sodium 2-bromo-2,2-difluoroacetate (5.46 g), Cs2CO3 (27.09 g), KI (4.59 g), and TBAI (10.22 g) were added to DMF (200 mL) and stirred at 100° C. for 3 h. The reaction was diluted with DCM and washed with saturated NaCl solution. The crude product was purified by column chromatography (PE:DCM=1 / 1) to give 5 g of methyl 2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carboxylate.

[0414] Step 5: Preparation of (2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methanol

[0415] [ka]

[0416] To a solution of methyl 2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carboxylate (1.30 g) in THF (50 ml) was added a solution of LiAlH4 in THF (2.5 M) dropwise at -10 °C. The mixture was allowed to warm to room temperature. After 1 h, the mixture was quenched with 1 mL of H2O and 1 mL of 10% NaOH solution and washed with 1 M HCl, water and brine. The organic layer was dried over Na2SO4, filtered and the filtrate was concentrated. This gave (2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methanol (1.2 g) as a yellow solid.

[0417] Step 6: Preparation of 2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carbaldehyde

[0418] [ka]

[0419] To a solution of (2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methanol (1.40 g) in dry THF (15 mL) was added Dess-Martin (2.39 g) in portions at 10° C. The resulting solution was stirred at room temperature for 1 h. The mixture was filtered through Celite. The solid was washed with DCM and the combined filtrate was washed with aqueous sodium bicarbonate, water and brine, dried and concentrated. The residue was purified by column chromatography (eluted with a gradient of hexane-EtOAc from 20:1 to 5:1) to give 2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carbaldehyde (1.27 g).

[0420] Step 7: Preparation of ((2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy))benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0421] [ka]

[0422] A solution of 2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carbaldehyde (1.0 g), methyl L-proline (1.7 g), and HOAC (316 mg) in MeOH was stirred at room temperature for 30 min. NaBH3CN (498 mg) was added and heated at 60° C. for 2 h. The mixture was cooled, diluted with DCM, and washed with H2O and aqueous NaCl. The organic phase was dried over MgSO4, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (DCM:MeOH=10:1) to give 671 mg of ((2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl as a white solid.

[0423] Step 8: Preparation of ((6-(difluoromethoxy)-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0424] [ka]

[0425] To a solution of ((2-(3-bromo-2-methylphenyl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl (680 mg) in 1,4-dioxane (16.0 mL) was added bis(pinacolato)diboron (1.20 g), Pd(dppf)Cl2·DCM (100 mg), and KOAc (102 mg) under the protection of N2 gas. The mixture was heated at 100 °C for 10 h. It was diluted with 30 mL of water and then extracted with DCM (90 mL × 2). The combined organic extracts were washed with brine, dried over MgSO4, and concentrated in vacuum. The residue was purified on silica gel (eluted with a gradient of hexane-EtOAc from 4:1 to 2:1) to give ((6-(difluoromethoxy)-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl (500 mg). LC-MS (m / z): 543.2 (M+H). + .

[0426] Example B Synthesis of Intermediate B ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0427] [ka]

[0428] Step 1: Preparation of ((2-(3′-bromo-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0429] [ka]

[0430] Under the protection of N2 gas, to a solution of intermediate A (21.7 g), 1-bromo-3-iodo-2-methylbenzene (9.0 g) in toluene (150 mL) was added EtOH (30 mL), 10% aqueous Na2CO3 (30 mL), and Pd(dppf)Cl2·DCM (1.0 g). The mixture was stirred at 90 °C overnight. It was quenched with H2O (100 mL) and extracted three times with EtOAc (100 mL). The organic layers were combined and washed with brine. The resulting solution was concentrated and purified on silica gel (eluted with a gradient of hexane-EtOAc from 10:1 to 4:1) to give ((2-(3′-bromo-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl (18.2 g) as a brown oil.

[0431] Step 2: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0432] [ka]

[0433] Under the protection of N2 gas, bis(pinacolato)diboron (12.4 g), Pd(dppf)Cl2·DCM (1.0 g) and KOAc (9.9 g) were added to a solution of compound b-1 (18.2 g) in 1,4-dioxane (120 ml). It was heated at 100 °C for 6 h. It was diluted with 300 mL of water and then extracted three times with EtOAc (150 mL). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuum. The residue was purified on silica gel (eluted with a gradient of hexane-EtOAc from 20:1 to 10:1) to give ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl (15.1 g) as a brown oil. LC-MS (m / z): 633.9 (M+H). + .

[0434] Example 1 Synthesis of Compound 1 ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0435] [ka]

[0436] Step 1: Preparation of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(hydroxymethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0437] [ka]

[0438] Compound a-6 (3.9 g), K2CO3 (3.8 g) and Pd(dppf)Cl2·CH2Cl2 (732 mg) were added to a mixture of intermediate A (5 g) in 1,4-dioxane (80 mL) / H2O (16 ml). The mixture was stirred at 80 °C for 12 h under N2 atmosphere. After the reaction of the raw material was almost completed and the reaction was stopped, the mixture was poured into H2O (300 mL) and extracted three times with DCM (100 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give a residue. The residue was further purified by silica gel column to give compound 1-1 (3.7 g).

[0439] Step 2: Preparation of ((2-(3′-(5-(chloromethyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0440] [ka]

[0441] Compound 1-1 (1.5 g) was dissolved in DCM (20 mL). SOCl2 (495 mg) was added dropwise and stirred at room temperature for 1 hour. The reaction was stopped until the raw material disappeared. The resulting mixture was concentrated under reduced pressure. This gave 1.56 g of compound 1-2 (crude).

[0442] Step 3: Preparation of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0443] [ka]

[0444] A mixture of compound 1-2 (300 mg), (1S,2R)-2-aminocyclopentan-1-ol (168 mg), K2CO3 (283 mg), and KI (68 mg) in CH3CN (10 ml) was stirred at 50°C for 1.5 hours. After the reaction of the raw material was almost completed and the reaction was stopped, the reaction solution was poured into H2O (30 mL) and extracted three times with DCM (15 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was further purified by silica gel column (DCM / MeOH) to obtain compound 1-3 (240 mg).

[0445] Step 4: Preparation of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl))amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0446] [ka]

[0447] A mixture of compound 1-3 (240 mg), HCHO (45 mg), CH3COOH (36 mg) in MeOH (5 mL) / DCM (5 mL) was stirred at 30 °C for 30 min, then NaBH3CN (57 mg) was added and stirring was continued until the reaction of the raw material was almost complete and the reaction stopped. The reaction solution was poured into H2O (30 mL) and extracted three times with DCM (15 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by silica gel column (DCM / MeOH) to give compound 1-4 (200 mg).

[0448] Step 5: Preparation of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline (compound 1)

[0449] [ka]

[0450] Compound 1-4 (200 mg) and LiOH (51 mg) were dissolved in a mixture of THF (8 mL) / HO (2 mL) and stirred at 35° C. for 12 h. The reaction mixture was poured into HO (30 mL) and extracted three times with DCM (10 mL) / MeOH (5 mL). The organic layers were combined, dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. As a result, 160 mg of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline (compound 1) was obtained. LC-MS (m / z): 803.3 (M+H) + .

[0451] Example 2 Synthesis of Compound 2 (2'S)-(((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-2,5-diyl))bis(methylene))di-L-proline

[0452] [ka]

[0453] Step 1: Preparation of methyl 6-(difluoromethoxy)-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d]oxazole-5-carboxylate

[0454] [ka]

[0455] To a solution of compound a-5 (880 mg) in 1,4-dioxane (16.0 ml) were added bis(pinacolato)diboron (1.80 g), Pd(dppf)Cl2·DCM (150 mg) and KOAc (130 mg). The mixture was heated at 100° C. for 10 h. It was diluted with 30 mL of water and then extracted with DCM (90 mL×2). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuo to give a residue. The residue was purified by silica gel (eluted with a gradient of hexane-EtOAc from 4:1 to 2:1) to give compound 2-1 (600 mg).

[0456] Step 2: Preparation of 2,2′-(2,2′-dimethyl-[1,1′-biphenyl]-3,3′-diyl)bis(dimethyl 6-(difluoromethoxy)benzo[d]oxazole-5-carboxylate)

[0457] [ka]

[0458] A mixture of compound 2-1 (8 g), compound a-5 (8.95 g), K2CO3 (5.25 g) and Pd(dppf)Cl2·DCM (1.65 g) in 1,4-dioxane (160 ml) / H2O (16 ml) was evacuated and filled with nitrogen gas three times. The mixture was heated to reflux for 2 h. The reaction was added with 200 mL of H2O and extracted with EtOAc (2×200 mL). The combined organic layers were washed with brine (100 ml) and then dried over Na2SO4. The resulting solution was filtered and concentrated to give a residue. The residue was purified by column chromatography (EA) to give compound 2-2 (6.3 g).

[0459] Step 3: Preparation of ((2,2′-dimethyl-[1,1′-biphenyl]-3,3′-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-2,5-diyl))dimethanol

[0460] [ka]

[0461] LiAlH4 (2.5M) was added dropwise to a solution of compound 2-2 (6.3 g) in THF (150 ml) at 0° C. and stirred for 30 min at 0° C. The reaction mixture was quenched with H2O at 0° C., and the mixture was dried over Na2SO4, filtered and concentrated to give material 2-3 (5.7 g).

[0462] Step 4: Preparation of 2,2′-(2,2′-dimethyl-[1,1′-biphenyl]-3,3′-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-5-carbaldehyde)

[0463] [ka]

[0464] Dess-Martin (11.95 g) was added to a solution of compound 2-3 (5.70 g) in THF (100 mL). The mixture was stirred at room temperature for 2 h. The reaction was quenched with NaHCO3 and Na2SO3 and extracted with EtOAc (2 x 100 ml). The combined organic layers were washed with brine (100 ml), dried over Na2SO4, filtered and concentrated to give compound 2-4 (5.5 g).

[0465] Step 5: Preparation of (2'S)-(((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-2,5-diyl)))bis(methylene))di-L-proline (compound 2)

[0466] [ka]

[0467] A mixture of compound 2-4 (4 g), L-proline (4.58 g) and AcOH (0.82 g) in MeOH (100 mL) was stirred for 30 min. NaBH3CN was added to the mixture and the mixture was stirred for 12 h. 200 mL of H2O was added to the reaction and extracted with DCM (2 x 200 mL). The combined organic layers were dried over Na2SO4. The resulting solution was filtered and concentrated to give the crude product. The crude product was purified by column chromatography (DCM / MeOH = 10:1) to give 2.56 g of ((2'S)-((((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-2,5-diyl))bis(methylene)))di-L-proline (compound 2). LC-MS(m / z):803.3(M+H) + .

[0468] Example 3 Synthesis of Compound 3 ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0469] [ka]

[0470] Step 1: Preparation of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-formylbenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0471] [ka]

[0472] (11.79 g) was added in portions to a solution of compound 1-1 (10.00 g) in THF (200 ml). The mixture was stirred at room temperature for 2 h. The reaction was quenched with Na2SO3 and aqueous sodium bicarbonate. The reaction was extracted with EtOAc (2 x 150 ml). The combined organic phase was washed with brine (100 ml), dried over Na2SO4, filtered and concentrated to give compound 3-1 (9.50 g).

[0473] Step 2: Preparation of ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0474] [ka]

[0475] A mixture of compound 3-1 (5.90 g), L-proline (2.85 g) and AcOH (0.51 g) in MeOH (60 mL) was stirred for 30 min. Then NaBH3CN (1.55 g) was added. The reaction was stirred for 3 h. The reaction was added 100 mL of H2O and extracted with DCM (2 x 100 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by column chromatography (DCM / MeOH=10:1) to give ((6-(difluoromethoxy)-2-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline (3.6 g). LC-MS (m / z): 817.3 (M+H) + .

[0476] Example 4 Synthesis of Compound 4 ((2-(2′-cyano-3′-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0477] [ka]

[0478] Step 1: Preparation of 2-bromo-6-vinylbenzonitrile

[0479] [ka]

[0480] A mixture of 2-bromo-6-iodobenzonitrile (10 g), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (5 g), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (2.5 g), and potassium carbonate (13.4 g) in 1,4-dioxane (100 mL) / H2O (20 mL) was stirred at 80 °C for 12 h under N2 atmosphere. The reaction solution was poured into H2O (30 mL) and extracted with DCM (15 mL × 3). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by silica gel column to give compound 4-1 (5 g).

[0481] Step 2: Preparation of 2-bromo-6-formylbenzonitrile

[0482] [ka]

[0483] Compound 4-1 (1 g) and sodium periodate (3.67 g) in THF The mixture in (20 mL) / H2O (6 mL) was stirred under ice bath, then potassium osmate (20 mg) was added, and the mixture was stirred at room temperature for 4 h. The reaction mixture was poured into H2O (150 mL), extracted twice with EA (100 mL), and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give the title compound 4-2 (800 mg).

[0484] Step 3: Preparation of 2-(3-bromo-2-cyanophenyl)-6-hydroxybenzo[d]oxazole-5-carboxylic acid

[0485] [ka]

[0486] A mixture of compound 4-2 (1 g) and 5-amino-2,4-dihydroxybenzoic acid methyl salt (870 mg) in MeOH (150 mL) was stirred at 80 °C for 2.5 h, then concentrated under reduced pressure and dissolved in dichloromethane. 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (1.3 g) was added to the solution and stirring was continued at room temperature. After 1 h, the mixture was filtered, the filter cake was washed with dichloromethane, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was suspended in methanol, the solution was filtered, and the filter cake was dried in a vacuum oven to give the title compound 4-3 (1.4 g).

[0487] Step 4: Preparation of methyl 2-(3-bromo-2-cyanophenyl)-6-(difluoromethoxy)benzo[d]oxazole-5-carboxylate

[0488] [ka]

[0489] A stirred solution of 2-(3-bromo-2-cyanophenyl)-6-hydroxybenzo[d]oxazole-5-carboxylate (1 g) in DMF (20 mL) / HO (0.6 mL) was added with sodium chlorodifluoroacetate (850 mg) and cesium carbonate (2.62 g), heated to 80° C., and stirred for 4 h. The mixture was then poured into HO (100 mL) and extracted twice with EA (80 mL). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and concentrated to give the crude product. The crude product was further purified by silica gel column to give the title compound 4-4 (800 mg).

[0490] Step 5: Preparation of 2-bromo-6-(6-(difluoromethoxy)-5-(hydroxymethyl)benzo[d]oxazol-2-yl)benzonitrile

[0491] [ka]

[0492] This compound was prepared using a procedure similar to that of Example A, step 5, replacing compound a-4 with compound 4-4 in step 5 of Example A. The mixture was concentrated under reduced pressure to give the title compound 4-5.

[0493] Step 6: Preparation of 2-bromo-6-(5-(chloromethyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)benzonitrile

[0494] [ka]

[0495] This compound was prepared using a procedure similar to that of step 2 of example 1, replacing compound 1-1 with compound 4-5 in step 2 of example 1. The crude product was used directly in the next step.

[0496] Step 7: Preparation of 2-bromo-6-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)benzonitrile

[0497] [ka]

[0498] This compound was prepared using a procedure similar to that of step 3 of example 1. In step 3 of example 1, compound 1-2 was replaced with compound 4-6, and (1S,2R)-2-aminocyclopentan-1-ol was replaced with 3,3-dimethylazetidine. The crude product was further purified by silica gel column (PE / EA) to give the title compound (290 mg).

[0499] Step 8: Preparation of ((2-(2'-cyano-3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0500] [ka]

[0501] This compound was prepared using the same procedure as in step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 4-7. The crude product was further purified by silica gel column to give the title compound.

[0502] Step 9: Preparation of ((2-(2'-cyano-3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0503] [ka]

[0504] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 4-8. The mixture was concentrated under reduced pressure to give the title compound. LC-MS (m / z): 784.3 (M+H). + .

[0505] The compounds in Table 1 were prepared in a similar manner to Examples 1-4 via different reaction starting materials and appropriate reagents.

[0506] [Table 1] TIFF0007579789000049.tif222170TIFF0007579789000050.tif221170TIFF0007579789000051.t if230170TIFF0007579789000052.tif230170TIFF0007579789000053.tif230170TIFF00075797890 00054.tif235170TIFF0007579789000055.tif226170TIFF0007579789000056.tif221170TIFF000 7579789000057.tif234170TIFF0007579789000058.tif226170TIFF0007579789000059.tif194170

[0507] Example 100 Synthesis of Compound 100 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0508] [ka]

[0509] Step 1: Preparation of 4-hydroxy-3-nitro-5-(trifluoromethyl)benzaldehyde

[0510] [ka]

[0511] 4-Hydroxy-3-(trifluorometal)benzaldehyde (1 g) was dissolved in concentrated H2SO4 (10 mL). After the mixture was cooled to 5°C (ice bath), concentrated HNO3 (65%) (612 mg) was added dropwise and stirred for another 30 minutes. After the reaction of the raw materials was almost completed and the reaction was stopped, the mixture was poured into ice water (30 mL) and separated by filtration. This gave compound 100-2 (1 g).

[0512] Step 2: Preparation of 2-nitro-4-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)phenol

[0513] [ka]

[0514] A mixture of compound 100-2 (500 mg), pyrrolidine (454 mg), and CH3COOH (255 mg) in 1,4-dioxane (10 mL) was stirred at 30 °C for 30 minutes, and then sodium borohydride triacetate (1.35 g) was added and stirring was continued. After the reaction of the raw material was almost completed and the reaction was stopped, the reaction solution was poured into H2O (30 mL), extracted three times with DCM (15 mL), extracted with brine, dried with anhydrous Na2SO4, the precipitate was filtered, dried under reduced pressure, and the crude product was further purified on a silica gel column (DCM:MeOH = = 10:1) to obtain compound 100-3 (420 mg).

[0515] Step 3: Preparation of 2-amino-4-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)phenol

[0516] [ka]

[0517] A mixture of compound 100-3 (420 mg) and 10% Pd(OH) / C (150 mg) in methanol (10 mL) was stirred at room temperature for 3 hours under a hydrogen gas atmosphere at 1.1 atm. The catalyst was then removed by filtration, the solid residue was washed with methanol (300 mL), and the solvent was removed under reduced pressure. This gave 300 mg of compound 100-4.

[0518] Step 4: Preparation of 2-(3-bromo-2-methyl-phenyl)-5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)-1,3-benzoxazole

[0519] [ka]

[0520] This compound was prepared using a procedure similar to that of step 3 of Example A. In step 3 of Example A, compound a-3 was replaced with compound 100-4. The crude product was used directly in the next step.

[0521] Step 5: Preparation of methyl (2S)-1-[[6-(difluoromethoxy)-2-[2-methyl-3-[2-methyl-3-[5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)-1,3-benzoxazol-2-yl]phenyl]phenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylate

[0522] [ka]

[0523] Intermediate A (345.72 mg), compound 100-5 (280 mg), 1,1′-bis(diphenylphosphino)ferrocene palladium M(II) dichloride (53 mg), and potassium carbonate (88.10 mg) were dissolved in 1,4-dioxane (8 mL) and H2O (2 mL) and stirred at 80 °C for 12 h under N2 gas. The reaction was poured into H2O (30 mL) and extracted three times with DCM (15 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by silica gel column to give compound 100-6 (300 mg).

[0524] Step 6: Preparation of (2S)-1-[[6-(difluoromethoxy)-2-[2-methyl-3-[2-methyl-3-[5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)-1,3-benzoxazol-2-yl]phenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylic acid (compound 100)

[0525] [ka]

[0526] This compound was prepared using a procedure similar to step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 100-6, and the precipitate was filtered and dried under reduced pressure. This gave (2S)-1-[[6-(difluoromethoxy)-2-[2-methyl-3-[2-methyl-3-[5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)-1,3-benzoxazol-2-yl]phenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylic acid (compound 100). LC-MS (m / z): 761.3 (M+H) + .

[0527] Example 101 Synthesis of Compound 101 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0528] [ka]

[0529] Step 1: Preparation of methyl 4-hydroxy-2-(trifluoromethyl)benzoate

[0530] [ka]

[0531] Methyl 4-hydroxy-2-(trifluoromethyl)benzoate: Concentrated sulfuric acid (10 ml) was added dropwise to a solution of 4-hydroxy-2-(trifluoromethyl)benzoic acid (18.0 g) in methanol (300 ml), and the mixture was stirred under reflux for 12 hours. After cooling to room temperature, water (200 ml) was added to the reaction mixture, methanol was removed under reduced pressure, and the mixture was extracted twice with ethyl acetate (200 ml). The organic layer was washed with water, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (18 g).

[0532] Step 2: Preparation of methyl 4-hydroxy-5-nitro-2-(trifluoromethyl)benzoate

[0533] [ka]

[0534] This compound was prepared using a procedure similar to that of Example 100, Step 1. In Example 100, Step 1, compound 100-1 was replaced with compound 101-1. The crude product was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound.

[0535] Step 3: Preparation of methyl 5-amino-4-hydroxy-2-(trifluoromethyl)benzoate

[0536] [ka]

[0537] This compound was prepared using a procedure similar to that of Example 100, step 3. In step 3 of Example 100, compound 100-3 was replaced with compound 101-2. The filtrate was concentrated under reduced pressure to give the title compound.

[0538] Step 4: Preparation of methyl 2-(3-bromo-2-methylphenyl)-6-(trifluoromethyl)benzo[d]oxazole-5-carboxylate

[0539] [ka]

[0540] This compound was prepared using the same procedure as in step 3 of Example A. In step 3 of Example A, compound a-3 was replaced with compound 101-3. The crude product was suspended in methanol, filtered and dried in a vacuum oven to obtain the title compound.

[0541] Step 5: Preparation of (2-(3-bromo-2-methylphenyl)-6-(trifluoromethyl)benzo[d]oxazol-5-yl)methanol

[0542] [ka]

[0543] This compound was prepared using a procedure similar to that of Example A, step 5. In step 5 of Example A, compound a-5 was replaced with compound 101-4. The filtrate was concentrated under reduced pressure to give the title compound.

[0544] Step 6: Preparation of 2-(3-bromo-2-methylphenyl)-5-(chloromethyl)-6-(trifluoromethyl)benzo[d]oxazole

[0545] [ka]

[0546] This compound was prepared using a procedure similar to that of step 2 of example 1. In step 2 of example 1, compound 1-1 was replaced with compound 101-5. The crude product was used directly in the next step.

[0547] Step 7: Preparation of 2-(3-bromo-2-methylphenyl)-5-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)benzo[d]oxazole

[0548] [ka]

[0549] This compound was prepared using a procedure similar to that of step 3 of example 1. In step 3 of example 1, compound 1-2 was replaced with compound 101-6, and (1S,2R)-2-aminocyclopentan-1-ol was replaced with pyrrolidine. The crude product was further purified by silica gel column (PE / EA) to give the title compound.

[0550] Step 8: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0551] [ka]

[0552] This compound was prepared using the same procedure as in step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 101-7. The crude product was further purified by silica gel column to give the title compound.

[0553] Step 9: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0554] [ka]

[0555] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 101-8. The mixture was concentrated under reduced pressure to give the title compound. LC-MS (m / z): 761.3 (M+H). + .

[0556] Example 102 Synthesis of Compound 102 ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0557] [ka]

[0558] Step 1: Preparation of methyl 2,3-difluoro-4-hydroxy-5-nitrobenzoate

[0559] [ka]

[0560] This compound was prepared using the same procedure as in step 1 of Example A. In step 1 of Example A, compound a-1 was replaced with methyl 2,3-difluoro-4-hydroxybenzoate. The crude product was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound.

[0561] Step 2: Preparation of methyl 5-amino-2,3-difluoro-4-hydroxybenzoate

[0562] [ka]

[0563] This compound was prepared using a procedure similar to that of Example A, step 2. In step 2 of Example A, compound a-2 was replaced with compound 102-1. The filtrate was concentrated under reduced pressure to give the title compound.

[0564] Step 3: Preparation of methyl 2-(3-bromo-2-methylphenyl)-6,7-difluorobenzo[d]oxazole-5-carboxylate

[0565] [ka]

[0566] This compound was prepared using the same procedure as in step 3 of Example A. In step 3 of Example A, compound a-3 was replaced with compound 102-2. The crude product was dissolved in methanol, filtered and dried in a vacuum oven. The title compound was obtained.

[0567] Step 4: Preparation of (2-(3-bromo-2-methylphenyl)-6,7-difluorobenzo[d]oxazol-5-yl)methanol

[0568] [ka]

[0569] This compound was prepared using a procedure similar to that of Example A, step 5. In step 5 of Example A, compound a-5 was replaced with compound 102-3. The filtrate was concentrated under reduced pressure to give the title compound.

[0570] Step 5: Preparation of ((2-(3′-(6,7-difluoro-5-(hydroxymethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0571] [ka]

[0572] This compound was prepared using the same procedure as in step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 102-4. The crude product was further purified by silica gel column to give the title compound.

[0573] Step 6: Preparation of ((2-(3′-(5-(chloromethyl)-6,7-difluorobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0574] [ka]

[0575] This compound was prepared using a procedure similar to that of step 2 of example 1. In step 2 of example 1, compound 1-1 was replaced with compound 102-5. The crude product was used directly in the next step.

[0576] Step 7: Preparation of ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0577] [ka]

[0578] This compound was prepared using a procedure similar to that of step 3 of example 1. In step 3 of example 1, compound 1-2 was replaced with compound 102-6, and (1S,2R)-2-aminocyclopentan-1-ol was replaced with pyrrolidine. The crude product was further purified by silica gel column (PE / EA) to give the title compound.

[0579] Step 8: Preparation of ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0580] [ka]

[0581] This compound was prepared using the same procedure as in step 5 of example 1. In the step of example 1, compound 1-4 was replaced with compound 102-7. The crude product was further purified on a silica gel column to give the title compound. LC-MS (m / z): 729.3 (M+H). + . 1H NMR (500 MHz, DMSO-d6)δ8.21(dd, J=7.9, 1.4Hz, 1H), 8.19-8.14(m, 2H), 8.08(s, 1H) , 7.82(s, 1H), 7.62-7.54(m, 2H), 7.51-7.44(m, 2H), 7.40(t, J=71.9Hz, 1H), 4.58(s, 2H), 4.36-4.20(m, 2H), 3.91(s, 1H), 3.46(s, 3H), 3.20-3.07(m, 2H) ), 2.96(s, 1H), 2.45(d, J=4.0Hz, 6H), 2.35-2.25(m, 1H), 2.08-1.76(m, 8H).

[0582] Example 103 Synthesis of Compound 103 ((2-(3′-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0583] [ka]

[0584] Step 1: Preparation of methyl 3-cyano-4-hydroxy-5-nitrobenzoate

[0585] [ka]

[0586] This compound was prepared using the same procedure as in step 1 of Example A. In step 1 of Example A, compound a-1 was replaced with methyl 3-cyano-4-hydroxybenzoate. The crude product was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound. Step 2: Preparation of methyl 3-amino-5-cyano-4-hydroxybenzoate

[0587] [ka]

[0588] This compound was prepared using a procedure similar to that of Example A, step 2. In step 2 of Example A, compound a-2 was replaced with compound 103-1. The filtrate was concentrated under reduced pressure to give the title compound.

[0589] Step 3: Preparation of methyl 2-(3-bromo-2-methylphenyl)-7-cyanobenzo[d]oxazole-5-carboxylate

[0590] [ka]

[0591] This compound was prepared using the same procedure as in step 3 of Example A. In step 3 of Example A, compound a-3 was replaced with compound 103-2. The crude product was further purified by silica gel column to give the title compound.

[0592] Step 4: Preparation of 2-(3-bromo-2-methylphenyl)-5-(hydroxymethyl)benzo[d]oxazole-7-carbonitrile

[0593] [ka]

[0594] This compound was prepared using a procedure similar to that of Example A, step 5. In step 5 of Example A, compound a-5 was replaced with compound 103-3. The filtrate was concentrated under reduced pressure to give the title compound.

[0595] Step 5: Preparation of ((2-(3′-(7-cyano-5-(hydroxymethyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)-L-prolinate methyl

[0596] [ka]

[0597] This compound was prepared using the same procedure as in step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 103-4. The crude product was further purified by silica gel column to give the title compound.

[0598] Step 6: Preparation of ((2-(3′-(5-(chloromethyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)-L-prolinate methyl

[0599] [ka]

[0600] This compound was prepared using a procedure similar to step 2 of example 1. In step 2 of example 1, compound 1-1 was replaced with compound 103-5. The crude product was used directly in the next step.

[0601] Step 7: Preparation of ((2-(3′-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0602] [ka]

[0603] This compound was prepared using a procedure similar to that of step 3 of example 1, except that compound 1-2 was replaced with compound 103-6 and (1S,2R)-2-aminocyclopentan-1-ol was replaced with 3,3-dimethylazetidine in step 3 of example 1. The crude product was further purified by silica gel column (PE / EA) to give the title compound.

[0604] Step 8: Preparation of ((2-(3′-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0605] [ka]

[0606] This compound was prepared using a procedure similar to that of step 5 of example 1. In step 5 of example 1, compound 1-4 was replaced with compound 103-7, and the crude product was further purified by silica gel column to give the title compound. LC-MS (m / z): 732.3 (M+H). + . 1 H NMR(500MHz,DMSO-d6)8.20(dd,J=7.9,1.4Hz,1H),8.16(dd,J=7.9,1.5Hz,1H),8.09(s,1H),7.97 (s,1H), 7.85(s,1H), 7.73(s,1H), 7.62-7.51(m,2H), 7.50-7.41(m,2H), 7.38(t,J=71.9Hz,1H), 3 .96(s,2H),3.75(s,2H),3.36(dd,J=9.1,5.4Hz,1H),3.07(td,J=9.4,8.4,3.3Hz,1H),2.99(s,3H) ), 2.56(q,J=8.5Hz,1H), 2.44(d,6H,J=2.5Hz), 2.17-2.08(m,1H), 1.90-1.68(m,4H), 1.20(s,6H).

[0607] The compounds in Table 2 were prepared in a similar manner to Examples 100-103 via different reaction starting materials and appropriate reagents.

[0608] [Table 2] TIFF0007579789000096.tif248170TIFF0007579789000097.tif223170TIFF0007579789000098.t if244170TIFF0007579789000099.tif243170TIFF0007579789000100.tif235170TIFF00075797890 00101.tif235170TIFF0007579789000102.tif231170TIFF0007579789000103.tif243170TIFF000 7579789000104.tif235170TIFF0007579789000105.tif235170TIFF0007579789000106.tif235170

[0609] Example 171 Synthesis of Compound 171 (S)-1-((8-((3′-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)-2-methylpyrrolidine-2-carboxylic acid

[0610] [ka]

[0611] Step 1: Preparation of 8-chloro-3-vinyl-1,7-naphthyridine

[0612] [ka]

[0613] A solution of compound 171-1 (2.43 g) in toluene (30 mL) was added to EtOH (10 mL), 10% aqueous Na2CO3 solution (10 mL) and Pd(dppf)C 12 ·DCM (420 mg) was added. Then, under N2 gas protection, 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborane (3.1 g) was added dropwise. Stirred at 100 °C for 16 h. The reaction was quenched with H2O (50 ml) and extracted with EtOAc three times. The organic layers were combined and washed with brine. The resulting solution was concentrated and purified on silica gel (eluted with a gradient of hexane-EtOAc from 8:1 to 5:1) to give 8-chloro-3-vinyl-1,7-naphthyridine (1.1 g) as a brown solid.

[0614] Step 2: Preparation of (8-chloro-1,7-naphthyridin-3-yl)methanol

[0615] [ka]

[0616] To a solution of compound 171-2 (380 mg) in 1,4-dioxane (20 mL) / water (20 mL), K2OsO4 (4.0 mg) was added and stirred at room temperature for 30 min. NaIO4 (1.0 g) was added in small portions at the same temperature. After stirring for 3 h, the mixture was quenched with saturated aqueous Na2S2O3 and extracted three times with DCM (40 ml). The organic layers were combined and dried over Na2SO4. The resulting solution was concentrated to give 8-chloro-1,7-naphthyridine-3-carbaldehyde.

[0617] The above 8-chloro-1,7-naphthyridine-3-carbaldehyde (320 mg) was dissolved in 20 ml of MeOH and NaBH4 (200 mg) was added in one portion. The resulting mixture was stirred at room temperature for 2 h and then quenched with water (30 mL). It was extracted three times with DCM (20 ml) and the organic phase was dried over Na2SO4. The resulting solution was concentrated and purified on silica gel (eluted with a gradient of DCM-EtOAc from 1:1 to 1:2) to give (8-chloro-1,7-naphthyridine-3-yl)methanol (240 mg) as a white solid.

[0618] Step 3: Preparation of (8-((3-bromo-2-methylphenyl)amino)-1,7-naphthyridin-3-yl)methanol

[0619] [ka]

[0620] To a microwave reaction vial was added 3-bromo-2-methylaniline (2.50 g), compound 171-3 (1.86 g), t-BuOH (15 mL) and HCl (4.0 M in 1,4-dioxane, 3 mL). The vial was capped and heated in a microwave oven at 100° C. for 4 h. It was diluted with 20 mL of water and then extracted with DCM (50 mL×2). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was concentrated and recrystallized from DCM:hexane (1:1) to give (8-((3-bromo-2-methylphenyl)amino)-1,7-naphthyridin-3-yl)methanol (2.0 g) as an off-white solid.

[0621] Step 4: Preparation of ((5-(difluoromethoxy)-2-(3′-((3-(hydroxymethyl)-1,7-naphthyridine-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-6-yl)methyl)-L-prolinate methyl

[0622] [ka]

[0623] Under N2 gas protection, EtOH (5 mL), 10% Na2CO3 aqueous solution (10 mL), and Pd(dppf)Cl2·DCM (78 mg) were added to a solution of compound 171-4 (0.69 g) and intermediate A (1.5 g) in toluene (15 mL). The mixture was stirred at 110 °C overnight. The reaction was quenched with H2O (20 mL) and extracted three times with EtOAc (50 mL). The organic layers were combined and washed with brine. The resulting solution was concentrated and purified on silica gel (eluted with a gradient of hexane-EtOAc from 3:1 to 1:1) to give compound 171-5 (0.88 g) as a brown oil.

[0624] Step 5: Preparation of (S)-1-((8-((3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)-2-methylpyrrolidine-2-carboxylate.

[0625] [ka]

[0626] To a solution of compound 171-5 (250 mg) and TEA (100 mg) in DCM (5.0 ml), MsCl (89 mg) was added dropwise at 0° C. and stirred at room temperature for 4 h. The resulting mixture was concentrated under reduced pressure and redissolved with THF (5 mL). Methyl (S)-2-methylpyrrolidine-2-carboxylate (143 mg) and KI (1 mg) were added to the solution, and the reaction was then continued to stir at room temperature overnight until the methanesulfonate was consumed. The residue was concentrated and directly purified by RP-column (mobile phase: MeCN:water=10:90, 0.1% HCl) to give compound 171-6 (105 mg) as an off-white solid.

[0627] Step 6: Preparation of (S)-1-((8-((3′-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)-2-methylpyrrolidine-2-carboxylic acid

[0628] [ka]

[0629] LiOH (40 mg) was added to a solution of compound 171-6 (105 mg) in THF / water = 1:1 (4 mL). The resulting mixture was stirred at room temperature for 24 hours. The THF layer was separated and purified by RP-column (mobile phase: MeCN: water (0.1% HCl) with a gradient of 10:90 to 30:70). 78 mg of (S)-1-((8-((3'-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)-2-methylpyrrolidine-2-carboxylic acid (compound 171) was obtained. LC-MS (m / z): 777.3 (M+H) + . 1 H NMR (500MHz, methanol-d4) δ9.23(d,1H,J=2.1Hz), 8.60(d,1H,J=2.0Hz), 8.20(dd,1H,J=7.9,1.5Hz), 8.07(s,1H), 7.76(s,1H), 7.69-69.63(m, 2H), 7.57(t,1H,J=7.8Hz), 7.53(t,1H,J=7.7Hz), 7.46(dd,1H,J=7.6,1.5Hz), 7.38(dd,H,J=7.6,1.4Hz), 7.35(d,1H,J=6.9Hz), 7.12(t,1H,J F-H=72.6Hz), 4.83(d,1H,J=13.2Hz), 4.74(d,1H,J=13.3Hz), 4.62(d,1H,J=13.2Hz), 4.49(d,1H,J=13.2Hz), 4.33(dd,1H,J=9.6,7.2Hz), 3.66-3.6 2(m,1H), 3.52-3.37(m,3H), 2.63-2.56(m,1H), 2.55(s,3H), 2.41-2.32 (m,1H), 2.29-2.14(m,4H), 2.09(s,3H), 2.06-1.98(m,2H), 1.75(s,3H).

[0630] The compounds in Table 3 were prepared in a similar manner to Example 171 via different reaction starting materials and appropriate reagents.

[0631] [Table 3] TIFF0007579789000115.tif123170

[0632] Example 314 Synthesis of Compound 314 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0633] [ka]

[0634] Step 1: Preparation of benzyl (3S,4S)-3-(3-bromo-2-methylbenzamido)-4-hydroxypiperidine-1-carboxylate

[0635] [ka]

[0636] 3-Bromo-2-methylbenzoic acid (800 mg), (3S,4S)-3-amino-4-hydroxypiperidine-1-carboxylate benzyl (931.13 mg), EDCI (1.43 g), HOBT (1.01 g) and TEA (1.13 g) were added successively to DCM (50 mL) and the mixture was stirred at room temperature overnight. The reaction solution was diluted with methylene chloride and washed successively with saturated aqueous sodium bicarbonate and aqueous sodium chloride. The organic phase was dried over Na2SO4 and concentrated to give (3S,4S)-3-(3-bromo-2-methylbenzamido)-4-hydroxypiperidine-1-carboxylate benzyl (1.4 g, crude) as a whiteish solid.

[0637] Step 2: Preparation of (S)-benzyl 3-(3-bromo-2-methylbenzamido)-4-oxopiperidine-1-carboxylate

[0638] [ka]

[0639] To a solution of compound 314-3 (1.4 g) in DCM (30 mL) at room temperature, Dess-Martin (2.65 g) was added in portions and stirred for 3 h. The reaction was monitored to be complete by LC-MS, and the reaction mixture was quenched with Na2S2O3 solution and extracted three times with EA. The organic layer was washed with aqueous NaHCO3, dried over Na2SO4, and concentrated to give (S)-benzyl 3-(3-bromo-2-methylbenzamido)-4-oxopiperidine-1-carboxylate (1.1 g, crude) as a pale yellow solid.

[0640] Step 3: Preparation of benzyl 2-(3-bromo-2-methylphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate

[0641] [ka]

[0642] A solution of POCl3 (757.52 mg) in 1,4-dioxane (5 mL) was added dropwise to a solution of compound 314-4 (891 mg) in 1,4-dioxane (15 mL). Then the temperature was raised to 105° C. and stirring was continued for 2 h. The reaction mixture was slowly added dropwise to ice water and extracted with ethyl acetate. The organic phase was washed with saturated aqueous NaHCO3 and saturated NaCl, dried over Na2SO4, and concentrated to give a residue, which was purified by chromatography (DCM:MeOH=20:1) to give compound 314-5 (800 mg) as a whiteish solid.

[0643] Step 4: Preparation of (S)-2-(3′-(6-(difluoromethoxy)-5-((2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate benzyl

[0644] [ka]

[0645] Compound 314-5 (800 mg), intermediate A (1015 mg), Pd(dppf)Cl2 (343 mg) and K2CO3 (129.38 mg) were added to a mixture of 1,4-dioxane (20 ml) and H2O (5 ml). The mixture was evacuated and backfilled with N2 three times, heated at 80 °C and stirred for 3 h. The reaction was monitored to be complete by LC-MS. The reaction mixture was concentrated and purified by TLC (PE:EA=1:3) to give (S)-2-(3′-(6-(difluoromethoxy)-5-((2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-benzyl carboxylate (800 mg) as an off-white solid.

[0646] Step 5: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0647] [ka]

[0648] Pd / C (200 mg) was added to a solution of compound 314-7 (800 mg) in MeOH (50 mL). Stirred at room temperature for 5 h under H2 atmosphere. The reaction mixture was filtered and concentrated to give ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl (500 mg, crude) as an off-white solid.

[0649] Step 6: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0650] [ka]

[0651] (CHO)n (72 mg) was added to a solution of compound 314-8 (500 mg) in DCM (30 mL) and MeOH (10 mL). After stirring for 30 min, NaBH3CN (150 mg) was added in portions and stirred at room temperature overnight. The reaction was concentrated and purified by TLC (DCM:MeOH=20:1) to give methyl ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinatomethyl (400 mg)) as an off-white solid.

[0652] Step 7: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0653] [ka]

[0654] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 314-9, and the crude product was purified by TLC purification (DCM:MeOH=4:1) to obtain 210 mg ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline (compound 314) as an off-white solid. LC-MS (m / z): 629.3 (M+H) + .

[0655] The compounds in Table 4 were prepared in a similar manner to Example 314 via different reaction starting materials and appropriate reagents.

[0656] [Table 4] TIFF0007579789000125.tif252170TIFF0007579789000126.tif231170TIFF0007579789000127.tif128170

[0657] Example 208 Synthesis of Compound 208 ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0658] [ka]

[0659] Step 1: Preparation of 1-bromo-3-(chloromethyl)-2-methylbenzene

[0660] [ka]

[0661] (3-Bromo-2-methylphenyl)methanol (20 g) was dissolved in DCM (200 ml) and stirred at room temperature, and 20 ml of SOCl2 was added slowly. The mixture was stirred for 2 hours and then concentrated to give 1-bromo-3-(chloromethyl)-2-methylbenzene (23.1 g).

[0662] Step 2: Preparation of 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-hydroxybenzaldehyde

[0663] [ka]

[0664] 1-Bromo-3-(chloromethyl)-2-methylbenzene (2.0 g), 5-chloro-2,4-dihydroxybenzaldehyde (2.34 g), potassium carbonate (3.78 g), and KI (1.51 g) were mixed in acetonitrile (20 mL) and stirred overnight at 80° C. The reaction was completed, and 20 mL of water was added, concentrated, filtered, and dried to give 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-hydroxybenzaldehyde (2.8 g).

[0665] Step 3: Preparation of 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-((5-(difluoromethoxy)pyridin-3-yl)methoxy)benzaldehyde

[0666] [ka]

[0667] Compound 208-3 (500 mg), (5-(difluoromethoxy)pyridin-3-yl)methanol (408 mg), potassium carbonate (585 mg), and KI (195 mg) were added to acetonitrile (10 mL), and the reaction mixture was stirred overnight at 80° C. 10 mL of water was added, and the mixture was concentrated, filtered, and dried to give 4-((3-bromo-2-methylbenzyl)oxy)-5-chloro-2-((5-(difluoromethoxy)pyridin-3-yl)methoxy)benzaldehyde (478 mg).

[0668] Step 4: Preparation of ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-formylphenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)-L-prolinate methyl

[0669] [ka]

[0670] Compound 208-4 (470 mg), intermediate A (597 mg) and potassium carbonate (236 mg) were added to 1,4-dioxane (12 mL) and water (3 mL) with stirring, then Pd(dppf)Cl2 was added under N2 atmosphere. The reaction mixture was heated to 80 °C and stirred overnight. The mixture was quenched with water (30 mL) and extracted with DCM (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate, filtered, concentrated and purified by column (DCM / MeOH: 15 / 1) to give compound 208-5 (550 mg).

[0671] Step 5: Preparation of ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)-L-prolinate methyl

[0672] [ka]

[0673] Compound 208-5 (270 mg), (R)-pyrrolidin-3-ol (80 mg), and glacial acetic acid (40 mg) were added to 10 mL of methanol with stirring, and the mixture was heated to 50° C. and stirred for 1 h. After the mixture was cooled to room temperature, sodium cyanoborohydride was added, and the mixture was stirred at room temperature for 2 h. The mixture was then diluted with water (10 mL), extracted with DCM (15 mL×3), and the organic layer was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column (DCM / MeOH=15 / 1) to give compound 208-6 (110 mg).

[0674] Step 6: Preparation of ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline (Compound 208)

[0675] [ka]

[0676] Compound 208-6 (110 mg) was added to 5 mL methanol with stirring, 8 mg LiOH was weighed and dissolved in 1 mL water, then added to the mixture, and the reaction mixture was heated to 35° C. overnight. 10 mL water was added to the mixture, and it was extracted with DCM (15 mL×3). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give 105 mg ((2-(3′-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline (compound 208). LC-MS (m / z): 905.3 (M+H) + .

[0677] The compounds in Table 5 were prepared in a similar manner to Example 208 via different reaction starting materials and appropriate reagents.

[0678] [Table 5]

[0679] Example 242 Synthesis of Compound 242 ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline

[0680] [ka]

[0681] Step 1: Preparation of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

[0682] [ka]

[0683] To a solution of 4-bromobenzaldehyde (9.25 g) in 1,4-dioxane (120 ml) was added bis(pinacolato)diboron (15.8 g), Pd(dppf)Cl2·DCM (0.48 g) and KOAc (20.0 g). Heat at 100 °C for 4 h. The mixture was diluted with 150 mL of water and then extracted with EtOAc (150 mL x 2). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silica gel (eluted with a gradient of hexane-EtOAc from 20:1 to 10:1) to give 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (11.2 g) as a white solid.

[0684] Step 2: Preparation of 3′-bromo-2′-methyl-[1,1′-biphenyl]-4-carbaldehyde

[0685] [ka]

[0686] To a solution of compound 242-2 (60 ml) in EtOH (20 ml), 10% Na2CO3aq (20 ml) and Pd(dppf)Cl2·DCM (420 mg) were added, followed by dropwise addition of 1-bromo-3-iodo-2-methylbenzene (9.0 g) under N2 atmosphere. The mixture was stirred at 100 °C for 16 h. The reaction was quenched with H2O (50 mL) and extracted three times with EtOAc (100 mL). The organic layers were combined and washed with brine. The resulting solution was concentrated and purified on silica gel (eluted with a gradient of hexane-EtOAc from 20:1 to 10:1) to give 3′-bromo-2′-methyl-[1,1′-biphenyl]-4-carbaldehyde (3.2 g) as a pale yellow solid.

[0687] Step 3: Preparation of 1-((3′-bromo-2′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3-fluoropyrrolidine

[0688] [ka]

[0689] 3′-Bromo-2′-methyl-[1,1′-biphenyl]-4-carbaldehyde (275 mg) was dissolved in 5 mL of DCM. 3-Fluoropyrrolidine (120 mg) and HOAC were added in one portion. The resulting mixture was stirred at room temperature for 1 h, then STAB (420 mg) was added in one portion at the same temperature. The reaction was stirred at room temperature for 3 h. The resulting mixture was quenched with saturated Na2CO3, extracted three times with EtOAc (20 ml), and the organic phase was dried over Na2SO4. The resulting solution was concentrated to give 1-((3′-bromo-2′-methyl-[1,1′-biphenyl]-4-yl)methyl)-3-fluoropyrrolidine (320 mg) as a colorless oil.

[0690] Step 4: Preparation of ((6-(difluoromethoxy)-2-(4″-(((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)prolinate methyl

[0691] [ka]

[0692] This compound was prepared using a procedure similar to that of step 4 of example 171. In step 4 of example 171, compound 171-4 was replaced with compound 242-4, and the resulting mixture was purified on a RP column (mobile phase: MeCN:water (0.1% HCl), using a gradient of 40:60 to 50:50) to give compound 242-5 (288 mg).

[0693] Step 5: Preparation of ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline

[0694] [ka]

[0695] This compound was prepared using a procedure similar to that of step 6 of example 171. In step 6 of example 171, compound 171-6 was replaced with compound 242-5, and the crude product was purified by RP-column (mobile phase: MeCN:water (0.1% HCl), using a gradient of 40:60 to 50:50) to give ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)prolinate methyl as a white solid (168 mg) (compound 242). LC-MS (m / z): 670.3 (M+H) + .

[0696] Example 243 Synthesis of Compound 243 ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline

[0697] [ka]

[0698] Step 1: Preparation of ((6-(difluoromethoxy)-2-(3″-fluoro-4″-formyl-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0699] [ka]

[0700] This compound was prepared using a procedure similar to that of step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with 4-bromo-2-fluorobenzaldehyde, intermediate A was replaced with intermediate B, and the resulting solution was concentrated and purified on silica gel (eluted with a gradient of 5:1 hexane-EtOAc) to give the title compound as a yellow oil.

[0701] Step 2: Preparation of ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)prolinate methyl

[0702] [ka]

[0703] This compound was prepared using a procedure similar to that of step 5 of Example 2. In step 5 of Example 2, compound 2-4 was replaced with compound 243-1, L-proline was replaced with pyrrolidine, and the resulting solution was concentrated to give the title compound as a colorless oil.

[0704] Step 5: Preparation of ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0705] [ka]

[0706] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 243-2. ​​The crude product was purified by RP-column (mobile phase: MeCN:water (0.1% HCl), using a gradient from 10:90 to 30:70) to give the title compound. LC-MS (m / z): 670.3 (M+H). + . 1 H NMR (500MHz, methanol-d4) δ: 8.16 (dd, 1H, J = 7.9, 1.5Hz), 8.07 (s, 1H), 7.76 (s, 1H), 7.70 (t, 1H, J = 7.7Hz), 7.50 (t, 1H, J = 7.7Hz), 7.43-7.27 (m, 5H), 7.20 (dd, 1H, J = 7.5, 1.4Hz), 7.12 (t, 1H, J F-H =72.6Hz),4.75(d,1H,J=13.1Hz),4.54(d,1H,J=13.1Hz),4.54(s,2H),4.37(dd,1H,J=9.5,7.4Hz),3.66-3.60(m,3H),3 .45-3.40(m,1H),3.29-3.23(m,2H),2.65-2.57(m,1H),2.49(s,3H),2.28-2.14(m,4H),2.10-2.00(m,3H),1.96(s,3H).

[0707] Example 244 Synthesis of Compound 244 ((6-(difluoromethoxy)-2-(3″-(difluoromethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0708] [ka]

[0709] Step 1: Preparation of 4-bromo-2-(difluoromethoxy)benzaldehyde

[0710] [ka]

[0711] To a solution of 4-bromo-2-hydroxybenzaldehyde (4.0 g) in DMF (50 ml) was added Cs2CO3 (9.8 g), KI (400 mg). The mixture was stirred at room temperature for 30 min, then sodium 2-bromo-2,2-difluoroacetate (6.0 g) was added in small portions. The mixture was stirred at 75° C. overnight. The mixture was diluted with 100 mL of water, then extracted three times with EtOAc (100 mL). The combined organic extracts were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified on silica gel (eluted with a gradient of hexane-EtOAc from 8:1 to 5:1) to give 4-bromo-2-(difluoromethoxy)benzaldehyde (2.8 g) as a brown oil.

[0712] Step 2: Preparation of 5-bromo-2-(pyrrolidin-1-ylmethyl)benzonitrile

[0713] [ka]

[0714] This compound was prepared using a procedure similar to that of step 5 of Example 2. In step 5 of Example 2, compound 2-4 was replaced with compound 244-1, L-proline was replaced with pyrrolidine, and the crude product was purified by silica gel (eluted with a gradient of DCM-MeOH from 20:1 to 10:1) to give the title compound.

[0715] Step 3: Preparation of ((6-(difluoromethoxy)-2-(3″-(difluoromethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0716] [ka]

[0717] This compound was prepared using the same procedure as in step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 244-2, intermediate A was replaced with intermediate B, and the resulting solution was concentrated and purified on silica gel (eluted with a gradient of hexane-EtOAc from 5:1 to 1:1) to give the title compound.

[0718] Step 4: Preparation of ((6-(difluoromethoxy)-2-(3″-(difluoromethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0719] [ka]

[0720] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 244-3. The crude product was purified using a RP column (mobile phase: MeCN:water (0.1% HCl), gradient 10:90 to 35:65) to give the title compound. LC-MS (m / z): 718.3 (M+H). + . 1 H NMR (500MHz, methanol-d4), δ:8.16(dd,1H,J=7.9,1.5Hz),8.07(s,1H),7.76(s,1H),7.73(d,1H) ,J=7.9Hz),7.50(t,1H,J=7.7Hz),7.42-7.36(m,3H),7.34(d,1H,J=1.4Hz),7.30(dd,1H,J=7. 7,1.4Hz),7.21(dd,1H,J=7.4,1.4Hz),7.13(td,2H,J=72.8,2.4Hz),4.73(d,1H,J=13.2Hz), 4.61(d1H,J=13.2Hz),4.53(s,2H),4.30(dd,1H,J=9.7,7.1Hz),3.69-3.56(m,3H),3.44-3.38 (m,1H),3.31-3.28(m,2H),2.62-2.55(m,1H),2.50(s,3H),2.23-2.15(m,4H),2.12-2.00(m,3H),1.96(s,3H)

[0721] Example 245 Synthesis of Compound 245 ((2-(3″-cyano-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0722] [ka]

[0723] Step 1: Preparation of 5-bromo-2-(bromomethyl)benzonitrile

[0724] [ka]

[0725] To a solution of 5-bromo-2-methylbenzonitrile (20.0 g), NBS (19.6 g) in CCl4 (300 ml) was added BPO (2.4 g) under the protection of N2 gas. The mixture was stirred at 70°C overnight. The reaction was quenched with saturated NaHCO3 solution (200 ml). The organic layers were combined and washed with brine. The resulting solution was concentrated and purified on silica gel (eluted with a gradient of hexane-EtOAc from 20:1 to 1:1) to give 5-bromo-2-(bromomethyl)benzonitrile (15.2 g) as a yellow solid crude product.

[0726] Step 2: Preparation of 5-bromo-2-(pyrrolidin-1-ylmethyl)benzonitrile

[0727] [ka]

[0728] Pyrrolidine (2.85 g) was added dropwise to a solution of compound 245-1 (5.4 g) in THF (60 ml) at 0° C. and heated at 40° C. for 5 h. The reaction mixture was diluted with 200 mL of water and then extracted three times with EtOAc (150 mL). The combined organic extracts were washed with brine, dried over MgSO4, and concentrated in vacuo. The residue was purified on silica gel (eluted with a gradient of hexane-EtOAc from 2:1 to 1:2) to give 5-bromo-2-(pyrrolidin-1-ylmethyl)benzonitrile (3.8 g) as a brown oil.

[0729] Step 3: Preparation of ((2-(3″-cyano-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0730] [ka]

[0731] This compound was prepared using a procedure similar to that of step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 245-2, and intermediate A was replaced with intermediate B. The crude product was purified on silica gel (eluted with a gradient of hexane-EtOAc from 5:1 to 1:1) to give the title compound.

[0732] Step 4: Preparation of ((2-(3″-cyano-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0733] [ka]

[0734] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 245-3, and the crude product was purified by RP-column (mobile phase: MeCN:water (0.1% HCl), using a gradient of 10:90 to 35:65) to give the title compound. LC-MS (m / z): 677.3 (M+H). + . 1 H NMR (500MHz, methanol-d4) δ: 8.21 (dd, 1H, J = 7.9, 1.5Hz), 8.10 (s, 1H), 7.76 (s, 1H), 7.70 (t, 1H, J = 7.7Hz), 7.50 (t, 1H, J = 7.7Hz), 7.49-7.28 (m, 5H), 7.20 (dd, 1H, J = 7.5, 1.4Hz), 7.12 (t, 1H, J F-H=72.6Hz),4.73(d,1H,J=13.1Hz),4.51(d,1H,J=13.1Hz),4.51(s,2H),4.37(dd,1H,J=9.5,7.4Hz),3.69-3.51(m,3H),3 .47-3.42(m,1H),3.25-3.20(m,2H),2.65-2.57(m,1H),2.49(s,3H),2.28-2.12(m,4H),2.10-2.00(m,3H),1.96(s,3H).

[0735] Example 246 Synthesis of Compound 246 ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0736] [ka]

[0737] Step 1: Preparation of ((6-(difluoromethoxy)-2-(3′-(5-formyl-6-methoxypyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0738] [ka]

[0739] This compound was prepared using the same procedure as in step 1 of example 1. In step 1 of example 1, compound a-6 was converted to 6-chloro-2-methoxynicotinaldehyde, and intermediate A was replaced with intermediate B. The crude product was purified on silica gel (hexane-EtOAc=3:1) to obtain the title compound.

[0740] Step 2: ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0741] [ka]

[0742] This compound was prepared using a procedure similar to that of step 5 of Example 2. In step 5 of Example 2, compound 2-4 was replaced with compound 246-1, L-proline was replaced with (S)-3-methylpyrrolidine, and the resulting solution was concentrated to give the title compound.

[0743] Step 3: (6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0744] [ka]

[0745] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 246-2. The organic layer was separated and purified by RP-column (mobile phase: MeCN:water (0.1% HCl), using a gradient of 15:85 to 30:70) to give (6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline (30.8 mg) as a white solid. LC-MS (m / z): 697.3 (M+H) + . 1H NMR(500MHz,DMSO-d6)δ8.11(dd,1H,J=7.9,1.5Hz),7.96(s,1H),7.77(d,1H,J=7.5Hz),7.72(s,1H),7.54 -7.37(m,5H),7.24-7.19(m,1H),7.16(d,1H,J=7.5Hz),3.95(s,2H),3.89(s,3H),3.58(s,2H),3.11-3.03 (m,1H),2.78(t,1H,J=2.8Hz),2.68-2.60(m,1H),2.60-2.52(m,3H),2.45(s,3H),2.22-2.16(m,1H),2.15 -2.07(m,2H),2.05(s,3H),2.02-1.93(m,1H),1.88-1.70(m,3H),1.34-1.27(m,1H),1.00(d,J=6.7Hz,3H).

[0746] Example 247 Synthesis of Compound 247 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0747] [ka]

[0748] Step 1: Preparation of (S)-2-(4-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate ter-butyl

[0749] [ka]

[0750] This compound was prepared using a procedure similar to that of step 1 of Example 1. In step 1 of Example 1, compound a-6 was replaced with (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate ter-butyl, intermediate A was replaced with intermediate B, concentrated, and purified on silica gel (eluted with a gradient of 5:1 to 1:1 hexane-EtOAc) to give (S)-2-(4-(3′-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate ter-butyl (98 mg) as a yellow oil.

[0751] Step 2: Preparation of methyl ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)-L-prolinate

[0752] [ka]

[0753] A mixture of compound 247-1 (76.0 mg) in DCM / TFA = 7:1 (4 mL) was stirred at room temperature for 4 hours. The resulting solution was concentrated under high vacuum to give compound 247-2 (60 mg) as a yellow semi-solid.

[0754] Step 3: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0755] [ka]

[0756] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 247-2, and the crude product was purified by RP-column (mobile phase: MeCN:water (0.1% HCl, using a gradient of 10:90 to 35:65) to obtain ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline (70.6 mg) as a white solid. MS (m / z): 628.3 (M+H) + . 1 H NMR (500MHz, methanol-d4), δ:8.19(dd,1H,J=8.0,1.5Hz),8.07(s,1H),7.76(d,1H,J=10.8Hz),7.61(dd,1H,J=7.8,1.3Hz) ,7.52(t,1H,J=7.8Hz),7.46(t,1H,J=7.6Hz),7.38(dd,1H,J=7.6,1.4Hz),7.32(dd,1H,J=7.6,1.4Hz),7.13(t,1H,J F-H =72.6Hz),5.16(t,1H,J=9.3,7.7Hz),4.79(d,1H,J=13.2),4.62(d,1H,J=13.3),4.48(t,1H,J=9.3Hz),3.67-3.55(m,3H),3.50-3. 42(m,1H),2.75-2.60(m,2H),2.58-2.50(m,1H),2.49(s,3H),2.43-2.34(m,1H),2.29-2.17(m,3H),2.15(s,3H),2.11-1.99(m,1H).

[0757] The compounds in Table 6 were prepared in a similar manner to Examples 242-247 via different reaction starting materials and appropriate reagents.

[0758] [Table 6] TIFF0007579789000165.tif243170TIFF0007579789000166.tif251170TIFF0007579789000167.tif235170TIFF0007579789000168.tif226170 TIFF0007579789000169.tif235170TIFF0007579789000170.tif235170TIFF0007579789000171.tif244170TIFF0007579789000172.tif106170

[0759] Example 295 Synthesis of Compound 295 ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0760] [ka]

[0761] Step 1: Preparation of methyl 4-amino-3-iodo-5-nitrobenzoate

[0762] [ka]

[0763] Methyl 4-amino-3-nitrobenzoate (5 g) was added to a solution of Ag2SO4 (7.93 g) and I2 (6.47 g) in ethanol (20 ml) at room temperature. The mixture was stirred overnight at room temperature. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate. The organic layer was washed with aqueous Na2S2O3, dried over MgSO4, and evaporated to dryness. The residue was purified by silica gel chromatography to give the desired product methyl 4-amino-3-iodo-5-nitrobenzoate (7 g) as a yellow solid.

[0764] Step 2: Preparation of methyl 3,4-diamino-5-iodobenzoate

[0765] [ka]

[0766] To a solution of compound 295-1 (3 g) in EA (30 ml) was added SnCl2 (8.42 g). Stirred at 70° C. for 16 h. EA (50 ml) was added and the organic phase was washed with aqueous NaHCO3, dried over MgSO4 and evaporated to dryness. The residue was purified by silica gel chromatography to give the desired product, methyl 3,4-diamino-5-iodo-benzoate (2.6 g) as a yellow solid.

[0767] Step 3: Preparation of methyl 2-(3-bromo-2-methylphenyl)-7-iodo-1H-benzo[d]imidazole-5-carboxylate

[0768] [ka]

[0769] A mixture of compound 295-2 (2.6 g), 3-bromo-2-methyl-benzaldehyde (1.77 g) and AcOH (30 ml) was stirred at 80° C. for 16 h. EA (50 ml) was added to the mixture, and the organic phase was washed with water, dried over MgSO4 and evaporated to dryness. The residue was purified by silica gel chromatography to give the desired product, methyl 2-(3-bromo-2-methyl-phenyl)-7-iodo-1H-benzimidazole-5-carboxylate (3.2 g) as a yellow solid.

[0770] Step 4: Preparation of 2-(3-bromo-2-methylphenyl)-7-iodo-1H-benzo[d]imidazole-5-carboxylic acid

[0771] [ka]

[0772] To a solution of compound 295-3 (2 g) in MeOH (20 mL) was added a solution of NaOH (849.10 mg) in water (6 mL). The reaction mixture was stirred at 50° C. overnight. The mixture was concentrated. H2O (10 mL) was added to the mixture, the pH was adjusted to 5 with 2N HCl, the precipitate was filtered, the filter cake was washed with H2O, and the product was dried in a vacuum oven (45° C., 3 h) to give the title compound 2-(3-bromo-2-methylphenyl)-7-iodo-1H-benzimidazole-5-carboxylic acid (1.8 g) as an off-white solid.

[0773] Step 5: Preparation of (2-(3-bromo-2-methylphenyl)-7-iodo-1H-benzo[d]imidazol-5-yl)methanol

[0774] [ka]

[0775] To a solution of compound 295-4 (1.8 g) in THF (20 mL) was added borane-tetrahydrofuran complex (20 mL) at -30°C. The reaction mixture was stirred at 60°C for 16 h. The mixture was cooled to room temperature and 2N HCl (20 mL) was added. After 10 min, the mixture was diluted with hexane acetate and washed with water. The organic phase was dried over MgSO4 and evaporated to dryness. The residue was purified by silica gel chromatography to give the desired product [2-(3-bromo-2-methyl-phenyl)-7-iodo-1H-benzimidazol-5-yl]methanol (1 g) as a white solid.

[0776] Step 6: Preparation of 2-(3-bromo-2-methylphenyl)-5-(hydroxymethyl)-1H-benzo[d]imidazole-7-carbonitrile

[0777] [ka]

[0778] A mixture of compound 295-5 (500 mg), Zn(CN)2 (66.02 mg), and Pd(PPh3)4 (130.34 mg) in DMF (10 ml) was stirred at 90° C. for 3 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate. The organic layer was then washed with aqueous NaCl, dried over MgSO4, and evaporated to dryness. The residue was purified by silica gel chromatography to give the desired product 2-(3-bromo-2-methyl-phenyl)-6-(hydroxymethyl)-3H-benzimidazole-4-carbonitrile (150 mg) as a yellow oil.

[0779] Step 7: Preparation of 2-(3-bromo-2-methylphenyl)-5-(chloromethyl)-1H-benzo[d]imidazole-7-carbonitrile

[0780] [ka]

[0781] This compound was prepared using a procedure similar to that of step 2 of example 1. In step 2 of example 1, compound 1-1 was replaced with compound 295-6. The mixture was concentrated to give the title compound.

[0782] Step 8: Preparation of 2-(3-bromo-2-methylphenyl)-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazole-7-carbonitrile

[0783] [ka]

[0784] This compound was prepared using a procedure similar to that of step 3 of example 1. In step 3 of example 1, compound 1-2 was replaced with compound 295-7, and (1S,2R)-2-aminocyclopentan-1-ol was replaced with pyrrolidine. The crude product was purified by silica gel chromatography to give the title compound.

[0785] Step 9: Preparation of ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-prolinate methyl

[0786] [ka]

[0787] This compound was prepared using a procedure similar to that of step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 295-8. The crude product was purified by silica gel chromatography to give the title compound.

[0788] Step 10: Preparation of ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline

[0789] [ka]

[0790] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 295-9. The crude product was purified by pre-HPLC. The desired product (2S)-1-[[2-[3-[3-[7-cyano-5-(pyrrolidin-1-ylmethyl)-1H-benzimidazol-2-yl]-2-methyl-phenyl]-2-methyl-phenyl]-6-(difluoromethoxy)-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylic acid was obtained. LC-MS (m / z): 717.3 (M+H). + .

[0791] The compounds in Table 7 were prepared in a similar manner to Example 295 via different reaction starting materials and appropriate reagents.

[0792] [Table 7] TIFF0007579789000185.tif31170

[0793] Example 304 Synthesis of Compound 304 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-methyl-5-(pyrrolidin-1-ylmethyl)oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0794] [ka]

[0795] Step-1: 2-Bromo-4-methyl-oxazole-5-carboxylate methyl

[0796] [ka]

[0797] tert-Tyrnitrite (2.24 g) was added to a suspension of methyl 2-amino-4-methyl-oxazole-5-carboxylate (1.7 g) CuBr2 (7.28 g) in acetonitrile (20 mL). The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate. The organic layer was then washed with aqueous NaCl, dried over MgSO4 and evaporated to dryness. The residue was purified by silica gel chromatography to give the desired product methyl 2-bromo-4-methyl-oxazole-5-carboxylate (800 mg) as a white solid.

[0798] Step-2: Preparation of methyl 2-(3-bromo-2-methyl-phenyl)-4-methyl-oxazole-5-carboxylate

[0799] [ka]

[0800] This compound was prepared using a procedure similar to that of Example 1, Step 1. The crude product was purified by silica gel chromatography to give the title compound.

[0801] Step-3: Preparation of [2-(3-bromo-2-methyl-phenyl)-4-methyl-oxazol-5-yl]methanol

[0802] [ka]

[0803] This compound was prepared using a procedure similar to that of Example A, step 5. In step 5 of Example A, compound a-4 was replaced with compound 304-2. The crude product was purified by silica gel chromatography to give the title compound.

[0804] Step-4: Preparation of 2-(3-bromo-2-methyl-phenyl)-5-(chloromethyl)-4-methyl-oxazole

[0805] [ka]

[0806] This compound was prepared using a procedure similar to that of step 2 of example 1. In step 2 of example 1, compound 1-1 was replaced with compound 304-3. The mixture was concentrated to give the title compound.

[0807] Step-5: Preparation of 2-(3-bromo-2-methyl-phenyl)-4-methyl-5-(pyrrolidin-1-ylmethyl)oxazole

[0808] [ka]

[0809] This compound was prepared using a procedure similar to that of step 3 of Example 1. In step 3 of Example 1, compound 1-2 was replaced with compound 304-4, and (1S,2R)-2-aminocyclopentan-1-ol was replaced with pyrrolidine. The crude product was purified by silica gel chromatography to give the title compound.

[0810] Step-6: Preparation of (2S)-1-[[6-(difluoromethoxy)-2-[2-methyl-3-[2-methyl-3-[4-methyl-5-(pyrrolidin-1-ylmethyl)oxazol-2-yl]phenyl]phenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylate methyl

[0811] [ka]

[0812] This compound was prepared using a procedure similar to that of step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 304-5. The crude product was purified by silica gel chromatography to give the title compound.

[0813] Step 7: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-methyl-5-(pyrrolidin-1-ylmethyl)oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0814] [ka]

[0815] This compound was prepared using a procedure similar to that of step 5 of example 1. In step 5 of example 1, compound 1-4 was replaced with compound 304-6. The crude product was purified by pre-HPLC to give the title compound. LC-MS (m / z): 657.3 (M+H). + .

[0816] Example 305 Synthesis of Compound 305 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0817] [ka]

[0818] Step-1: Preparation of ethyl N-[[5-(hydroxymethyl)-2-pyridyl]carbamothioyl]carbamate

[0819] [ka]

[0820] To a solution of (6-aminopyridin-3-yl)methanol (5 g) in 1,4-dioxane (25 mL) was added ethyl N-(thioxomethylene)carbamate (7.92 g). The reaction mixture was stirred at 50° C. for 3 hours. The mixture was concentrated to give a residue. The residue was used directly in the next step.

[0821] Step-2: Preparation of (2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)methanol

[0822] [ka]

[0823] To a solution of compound 305-1 (9.5 g) in methanol (15 mL) / ethanol (15 mL) was added hydroxylamine hydrochloride (5.13 g) followed by N,N-diisopropylethylamine (9.62 g). The reaction mixture was then stirred at 50° C. for 3 hours. The crude product was cooled and the precipitate was filtered to give the desired product (5.0 g) as a green oil.

[0824] Step-3: Preparation of (2-bromo-[1,2,4]triazolo[1,5-a]pyridin-6-yl)methanol

[0825] [ka]

[0826] tert-Butyl nitrite (5.6 g) was added to a suspension of compound 305-2 (5 g) and copper(II) bromide (1.22 g) in acetonitrile (50 mL). The mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with DCM and washed with water. The organic phase was dried, filtered, and concentrated to near dryness. The residue was purified by silica gel chromatography to give the desired product (3.2 g) as a white solid.

[0827] Step 4: Preparation of [2-(3-bromo-2-methyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]methanol

[0828] [ka]

[0829] This compound was prepared using a procedure similar to that of Example 1, Step 1. The residue was purified by silica gel chromatography to give the title compound.

[0830] Step-5: Preparation of 2-(3-bromo-2-methyl-phenyl)-6-(chloromethyl)-[1,2,4]triazolo[1,5-a]pyridine

[0831] [ka]

[0832] This compound was prepared using a procedure similar to that of step 2 of example 1. In step 2 of example 1, compound 1-1 was replaced with compound 305-4. The crude product was used directly in the next step.

[0833] Step-6: Preparation of 2-(3-bromo-2-methyl-phenyl)-6-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[1,5-a]pyridine

[0834] [ka]

[0835] This compound was prepared using a procedure similar to that of step 3 of Example 1. In step 3 of Example 1, compound 1-2 was replaced with compound 305-5, and (1S,2R)-2-aminocyclopentan-1-ol was replaced with pyrrolidine. The crude product was purified by silica gel chromatography to give the title compound.

[0836] Step 7: Preparation of methyl (2S)-1-[[6-(difluoromethoxy)-2-[2-methyl-3-[2-methyl-3-[6-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]phenyl]phenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylate

[0837] [ka]

[0838] This compound was prepared using a procedure similar to that of step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 305-6. The crude product was purified by silica gel chromatography to give the title compound.

[0839] Step 8: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0840] [ka]

[0841] This compound was prepared using a procedure similar to that of step 5 of example 1. In step 5 of example 1, compound 1-4 was replaced with compound 305-7. The crude product was purified by pre-HPLC to give the title compound. LC-MS (m / z): 693.3 (M+H). + .

[0842] Example 306 Synthesis of Compound 306 ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-(pyrrolidin-1-yl)piperidin-1-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0843] [ka]

[0844] Step-1: Preparation of 1-(3-bromo-2-methyl-phenyl)-4-pyrrolidin-1-yl-piperidine

[0845] [ka]

[0846] A mixture of 1,3-dibromo-2-methyl-benzene (1 g), 4-pyrrolidin-1-ylpiperidine (617.18 mg), Cs2CO3 (3.91 g), Pd2(dba)3 (366.10 mg), and Xantphos (462.53 mg) in toluene (20 ml) was stirred at 100° C. overnight. The mixture was concentrated to give a residue. The residue was purified by silica gel chromatography to give the desired product 1-(3-bromo-2-methyl-phenyl)-4-pyrrolidin-1-yl-piperidine (450 mg) as a red oil.

[0847] Step-2: Preparation of methyl (2S)-1-[[6-(difluoromethoxy)-2-[2-methyl-3-[2-methyl-3-(4-pyrrolidin-1-yl-1-piperidyl)phenyl]phenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-2-carboxylate

[0848] [ka]

[0849] This compound was prepared using a procedure similar to that of step 1 of example 1. In step 1 of example 1, compound a-6 was replaced with compound 306-1. The crude product was purified by silica gel chromatography to give the title compound.

[0850] Step-3: Preparation of ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-(pyrrolidin-1-yl)piperidin-1-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline

[0851] [ka]

[0852] This compound was prepared using a procedure similar to that of step 5 of Example 1. In step 5 of Example 1, compound 1-4 was replaced with compound 306-2. The crude product was purified by pre-HPLC to give the title compound. LC-MS (m / z): 645.3 (M+H). + .

[0853] The compounds in Table 8 were prepared in a similar manner to Examples 304-306 via different reaction starting materials and appropriate reagents.

[0854] [Table 8]

[0855] Compounds 34, 61, 85, 88, 93, 113, 127, 130, 131, 135, 142 and 146 1 The H NMR data is as follows:

[0856] 1 H NMR(500MHz,DMSO-d6)δ8.24(s,1H),8.17(dd,J=8.0,2.2Hz,2H),8.08(s,1H),7.88(s,1H),7.81(s,1H),7.64-7.51(m,2H),7.49-7.20 (m,4H),4.52(s,2H),4.38-4.12(m,2H),3.94-3.84(m,4H),3.26-2.86(m,3H),2.45(s,6H),2.37-1.71(m,4H),1.31(d,J=43.4Hz,6H). (Compound 34)

[0857] 1 H NMR (500MHz, chloroform-d) δ8.30-8.03(m,4H),7.66-7.54(m,2H),7.49-7.41(m,2H),7.40-7.35(m,2H),7.10-6.77(m,2H),4.86-4. 18(m,5H),3.94-3.57(m,3H),3.43-3.25(m,2H),2.71-2.55(m,2H),2.48(d,J=3.7Hz,6H),2.37-1.58(m,6H),1.27-1.08(m,3H). (Compound 61)

[0858] 1 H NMR(500MHz,クロロホルム-d)δ8.13(dd,J=7.8,6.1Hz,2H),7.99(d,J=9.8Hz,2H),7.52(d,J=1 7.9Hz,2H),7.48-7.42(m,2H),7.37-7.34(m,2H),6.83(t,J=71.9Hz,1H),6.80(t,J=71. 9Hz,1H),4.29(d,J=25.2Hz,4H),3.70(s,4H),3.42(dd,J=10.6,4.4Hz,1H),3.21(q,J=8.3Hz,2H),3.09(d,J=22.7Hz,2H),2.46(d,J=7.9Hz,6H),2.34-2.22(m,2H),1.35(s,6H). (Compound 85)

[0859] 1 H NMR(500MHz,クロロホルム-d)δ8.36(s,1H),8.22(dd,J=7.9,1.5Hz,1H),8.17-8.07(m,2H),7.99(s,1H),7.59 (s,1H),7.46(dt,J=12.7,7.7Hz,2H),7.42-7.34(m,2H),6.93(t,J=72.1Hz,1H),4.78-4.62(m,2H),4.5 2 (t, J = 12.8 Hz, 2H), 4.21 (t, J = 8.0 Hz, 1H), 3.87-3.58 (m, 3H), 3.21-3.00 (m, 2H), 2.75-2.53 (m, 3H), 2.47 (d, J = 15.4 Hz, 6H), 2.39-2.23 (m, 2H), 2.16 (t, J = 7.9 Hz, 2H), 1.78 (d, J = 62.1 Hz, 1H), 1.21-1.10 (m, 3H). (Compound 88)

[0860] 1H NMR (500 MHz, chromohol-d) δ 8.18 (d, J = 7.9 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.93-7.76 (m, 2H), 7.55 (s, 1H), 7.49-7.26 (m, 5H), 6.76 (t, J = 72.9 Hz, 1H), 4.29-3.39 (m, 6H), 3.23-2.91 (m, 6H), 2.38-2.47 (d, J = 25.5 Hz, 6H), 2.09-1.60 (m, 3H), 1.23 (s, 6H). (Compound 93)

[0861] 1 H NMR(500MHz,DMSO-d6))δ8.38(s,1H),8.26(s,1H),8.20(dd,J=7.9,1.4Hz,1H),8.13(ddd,J=23.5, 7.9,1.5Hz,1H),7.96(d,J=10.1Hz,1H),7.72(d,J=13.9Hz,1H),7.61-7.49(m,2H),7.45(ddd,J=13. 6,7.6,1.5Hz,2H),7.38(d,J=71.9Hz,1H),3.96(s,2H),3.44-3.22(m,5H),3.11-2.99(m,2H),2.57( q,J=8.5Hz,1H),2.45(d,J=5.8Hz,6H),2.19-2.06(m,1H),1.93-1.64(m,4H),1.22(d,J=7.5Hz,6H). (Compound 113)

[0862] 1H NMR(500MHz,クロロホルム-d)δ8.24(dd,J=7.9,1.4Hz,1H),8.17-8.07(m,2H),8.03(s,1H),7.79(s,1H), 7.60(s,1H),7.48(dt,J=15.0,7.7Hz,2H),7.43-7.35(m,2H),6.94(t,J=71.9Hz,1H),4.60(d,J=13. 1Hz, 1H), 4.50 (d, J = 13.2Hz, 1H), 3.97 (s, 3H), 3.71-3.60 (m, 1H), 3.15 (q, J = 9.9Hz, 1H), 2.76 (s, 4H), 2.47 (s, 6H), 2.33-2.24 (m, 1H), 2.15-2.06 (m, 1H), 2.06-1.97 (m, 2H), 1.91 (q, J = 3.5, 3.0Hz, 4H). (Compound 127)

[0863] 1 H NMR(500MHz,DMSO-d6)δ8.20(dd,J=7.9,1.4Hz,1H),8.16(dd,J=7.9,1.4Hz,1H),8.11(d,J=1.5Hz,1H),7. 97(s,1H),7.88(d,J=1.5Hz,1H),7.73(s,1H),7.63-7.51(m,2H),7.48(dd,J=7.6,1.4Hz,1H),7.44(dd,J= 7.6,1.4Hz,1H),7.38(t,J=73.7Hz,1H),3.96(s,2H),3.79-3.68(m,2H),3.38-3.31(m,1H),3.09-3.03(m,1H),2.74-2.48(m,5H),2.44(d,J=2.9Hz,6H),2.26-1.68(m,6H),1.36-1.20(m,1H),0.99(d,J=6.7Hz,3H). (Compound 130)

[0864] 1H NMR(500MHz,DMSO-d6)δ8.21(dd,J=7.9,1.4Hz,1H),8.19(s,1H),8.15(dd,J=7.9,1.4Hz,1H),7.97(s ,1H),7.95(s,1H),7.73(s,1H),7.63-7.51(m,2H),7.48(dd,J=7.6,1.4Hz,1H),7.44(dd,J=7.5,1.4H z, 1H), 7.38 (t, J = 73.7 Hz, 1H), 3.97 (s, 2H), 3.92-3.86 (m, 2H), 3.38-3.31 (m, 1H), 3.1-3.05 (m, 1H), 2.83-2.51 (m, 5H), 2.44 (d, J = 4.1 Hz, 6H), 2.31-1.70 (m, 6H), 1.46-1.14 (m, 1H), 1.00 (d, J = 6.3 Hz, 3H). (Compound 131)

[0865] 1 H NMR(500MHz,クロロホルム-d)δ8.25(d,J=7.8Hz,1H),8.14(dd,J=7.9,1.3Hz,1H),8.10(s,1H) ,7.94(s,1H),7.77(s,1H),7.61(s,1H),7.48(dt,J=15.2,7.7Hz,2H),7.42-7.34(m,2H) ,6.93(t,J=71.9Hz,1H),4.55(d,J=13.0Hz,1H),4.37(d,J=13.1Hz,2H),3.94-3.35(m,5H),3.17-2.82(m,4H),2.51(s,3H),2.47(s,3H),2.47-2.29(m,2H),2.16-1.46(m,10H). (Compound 135)

[0866] 1H NMR(500MHz,DMSO-d6)δ8.35-8.30(m,1H),8.23(dd,J=8.0,1.5Hz,1H),8.18(dt,J=7.9,1.3Hz,1H),8.12(d,J=1.4Hz, 1H),8.08(s,1H),7.89(s,1H),7.61(dt,J=13.6,7.7Hz,2H),7.57-7.45(m,2H),7.40(t,J=73.2Hz,1H),4.62-4.25(m, 4H),3.58-3.07(m,5H),2.52-2.50(m,1H),2.49-2.48(m,4H),2.45(d,J=5.5Hz,6H),2.26-1.80(m,4H). (Compound 142)

[0867] 1 H NMR(500MHz,DMSO-d6)δ8.35(s,1H),8.23(d,J=7.9Hz,1H),8.18(d,J=Hz,1H),8.13-8.07(m, 2H),7.87(s,1H),7.70(s,1H),7.60(dt,J=14.9,7.7Hz,2H),7.5-7.44(m,2H),7.32(t,J=73.2Hz,1H),4.56-4.01(m,7H),3 .50(s,2H),3.45-3.12(m,2H),2.56(s,2H),2.50-2.48(m,2H),2.45(d,J=5.5Hz,6H),2.43-2.33(m,1H)2.08-1.79(m,3H). (Compound 146)

[0868] (Comparative Example) The main components described in Example 7 of WO2018119266 are prepared as the following comparative examples (shown in Table 9).

[0869] [Table 9]

[0870] PD-1 / PD-L1 binding assay (Alphascreen) Measurements were performed in standard black 384-well polystyrene plates with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO and then added to the plate wells before adding other reaction components. In the measurements, the final concentration of the DMSO solution was 1%. 100 nL / well of compound was added to a 384 reaction plate (6008280, PerkinElmer) in an Echo and centrifuged at 1000 rpm for 1 min. 5 μL / well of 4XPD-L1 solution was added to the 384 reaction plate, centrifuged at 1000 rpm for 1 min, 5 μL / well of 4XPD-1 solution was added, centrifuged at 1000 rpm for 1 min, and incubated at 25° C. for 15 min. The concentrations of compounds were 300, 100, 33.33, 11.11, 3.70, 1.23, 0.41, 0.137, 0.046, 0.015, 0 nM, respectively. Add 10 μL / well 2X Anti-6xHis AlphaLISA Acceptor beads and Streptavidin Donor beads solution (PerkinElmer-AL356F) to the 384 reaction plate, centrifuge at 1000 rpm for 1 min, and incubate at 25 °C for 120 min in the dark. Read the AlphaLISA signal value using Envision Reader. Calculate IC by fitting the curve of percent control activity against logarithm of inhibitor concentration using GraphPad Prism 8.0 software. 50 The decision was made.

[0871] As illustrated in the embodiments of the present disclosure, IC 50 Values ​​are shown in the following ranges: * indicates 0.1 nM <IC 50 ≦5nM" and "**" indicates "5nM <IC 50 ≦50nM", and "***" indicates "IC 50 >50nM".

[0872] Data obtained for example compounds using the PD-1 / PD-L1 binding assay AlphaScreen (described above) are shown in Table 10.

[0873] [Table 10] TIFF0007579789000210.tif186170

[0874] Pharmacokinetic measurements Adult C57 female mice were treated with 10% DMSO as vehicle, 10% Kolliphor @ A single dose of test compound with HS 15 and 80% saline was administered to mice (n=9) at a dose of 100 mg / kg orally (intragastric administration). Blood collection times were: 15 min, 30 min, 1 h, 2 h, 4 h, 7 h, and 24 h. Approximately 0.1 ml of whole blood was collected from the retroorbital venous plexus of three mice at each time point and placed in a tube containing K2-EDTA as an anticoagulant. The whole blood was centrifuged at 4000 rpm for 10 min at 4 °C. The plasma was transferred to a centrifuge tube and stored at -20 °C before being analyzed. The concentration of the test compound in the plasma samples was analyzed by liquid chromatography / mass spectrometry (LC-MS / MS). The plasma concentration-time data of individual animals were analyzed using Microsoft Excel 2010. A non-compartmental model was introduced for the concentration analysis. Pharmacokinetic parameters of the test compounds were calculated using WinNonlin (version 4.1; Pharsight) software. The data are shown in Table 11.

[0875] Adult C57 female mice were treated with 15% DMSO as vehicle, 10% Kolliphor @A single dose of test compound containing HS 15 and 75% saline was administered to mice (n=3) at 5 mg / kg per dose, orally (intragastric administration). Blood collection times: 30 min, 2 h, and 4 h. Approximately 0.1 ml of whole blood was collected from the retroorbital venous plexus and placed in a tube containing K2-EDTA as an anticoagulant. Whole blood was centrifuged at 4000 rpm for 10 min at 4°C. Plasma was transferred to a centrifuge tube and stored at -20°C before being analyzed. The concentration of test compound in the plasma samples was analyzed by liquid chromatography / mass spectrometry (LC-MS / MS). Plasma concentration-time data of individual animals was analyzed using Microsoft Excel 2010. The data are shown in Table 12.

[0876] [Table 11]

[0877] [Table 12] TIFF0007579789000213.tif105170

[0878] As shown in Tables 11 and 12, the exemplified compounds of the present invention exhibit unexpectedly better pharmacokinetic properties than the known Comparative Example 1 compound.

[0879] NFAT measurement The PD-1 / PD-L1 Blockade Bioassay comprises two cells: PD-L1 effector cells, which are Jurkat T cells expressing hPD-1 and a luciferase reporter gene; and PD-L1 aAPC / CHO-K1 cells, which are CHO-K1 cells expressing hPD-L1 and activated TCR cell surface protein.

[0880] The antibody or small molecule compound is transiently incubated with these two cells, and the amount of product, as a reflection of the effect of the antibody or small molecule compound on the PD-1 / PD-L1 interaction, is detected by Bio-Glo luciferase reagent and chemiluminescence.

[0881] Measurement buffer: 49.5mL RPMI-1640; 0.5mL FBS Cell culture medium: 36mL Ham's F-12; 4mL FBS Reaction Process:

[0882] 1) On the first day, PD-L1 aAPC / CHO-K1 cells were resuscitated, suspended, and counted in cell collection medium. The cells were diluted to 2.65 × 10 5 The cells were diluted to / ml. The cells were seeded into 384-well plates at a density of 6000 cells / well and cultured in an incubator for 16-24 hours;

[0883] 2) Dilute the compound to 5 mM in DMSO. The 5 mM solution was used as the first concentration, and a 3-fold gradient dilution was performed for a total of 9 concentration gradients, with the 10th concentration used as a DMSO control;

[0884] 3) The positive control antibody Atezolizumab was diluted to 4 μg / ml in the assay buffer. 4 μg / ml was used as the first concentration, and a 2.5-fold gradient dilution was performed with a total of nine concentration gradients, with the tenth concentration used as the assay buffer control;

[0885] 4) Aspirate the medium from the 384-well plate. Add 10 μL / well compound to the 384-well plate and incubate for 2 hours;

[0886] 5) PD-1 effector cells were resuscitated, suspended, and counted in cell collection medium. The cells were diluted to 8.75 × 10 5 / ml. Seed the cells at a density of 8000 cells / well into the 384-well plate from step 4 and incubate for 17 hours;

[0887] 6) Add 20 μL / well of Bio-Glo Luciferase Test Solution to the 384-well plate from step 5 and incubate at 25°C for 5 to 30 minutes.

[0888] 7) Read the RLU (relative luminescence units) values ​​using an Envision multiplate reader. The experimental data was plotted using compound concentration as the X value and RLU as the Y value.

[0889] The result is EC 50 These are expressed as values ​​and are shown in Table 13.

[0890] [Table 13]

Claims

1. A compound of formula (I) or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, [Formula 1] In the formula, R 1 and R 2 are each independently selected from halogen, CN, C1-6 alkyl, or C1-4 haloalkyl; Q is -NH- or -(CH 2 ) m-O-bond; Ring A is a C5-6 aryl, C5-6 heteroaryl, C4-6 cycloalkyl, or C4-6 heterocycloalkyl, wherein said C5-6 heteroaryl and C4-6 heterocycloalkyl contain 1, 2, or 3 heteroatoms independently selected from N, S, or O; or Ring A is a C8-10 fused bicyclic ring; R 3 is H, halogen, -(CH 2 ) s -NR 4 R 5 , C1-4 alkyl, C1-4 alkoxyl, hydroxyl, oxo, CN, (CH 2 ) q -CONR 4 R 5 , -COR 4 , -NR 4 R 5 , -NR 4 C(=O)NR 4 R 5 , -NR 4 C (=NR 4 ) N.R. 4 R 5 , -S(O) 2 R 4 , -S(O) 2 N.R. 4 R 5 , -S(O)R 4 , -S(O)NR 4 R 5, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6 cycloalkyl, or C3-6 heterocycloalkyl, wherein said C5-6 heteroaryl and C3-6 heterocycloalkyl contain 1, 2, or 3 heteroatoms independently selected from N, S, or O; C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6 cycloalkyl, and C3-6 heterocycloalkyl are each independently selected from one or more R 6 optionally substituted with substituents; R 4 and R 5 are each independently selected from H, C1-4 alkyl, or C3-6 cycloalkyl, C3-6 heterocycloalkyl, and C1-4 alkyl, C3-6 cycloalkyl, or C3-6 heterocycloalkyl are each independently selected from one or more of R 6 optionally substituted with a substituent; or R 4 and R 5 together with the atoms to which they are attached, represent one or more independently selected substituents, R 6 may form a 4-10 membered heterocyclic ring optionally substituted with substituents; R 6 is H, halogen, hydroxy, oxo, CN, -(CH 2 ) k -NR 7 R 8 , -COR 7 , -NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -NR 7 C (=NR 7 ) N.R. 7 R 8 , -S(O) 2 R 7 , -S(O) 2 N.R. 7 R 8 , -S(O)R 7 , -S(O)NR 7 R 8 , or R 6 is selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocycle, wherein said C5-6 heteroaryl and C3-10 heterocycle contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; R 7 and R 8 are each independently H, halogen, hydroxy, oxo, CN, -S(O) 2 -C1-4 alkyl, -NH 2 , -NHC1-4 alkyl, -(CH 2 )-N(C1-4 alkyl) 2 or R 7 and R 8 is selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-6 cycloalkyl, C3-6 heterocycloalkyl, wherein said C5-6 heteroaryl and C3-6 heterocycloalkyl contain 1, 2, or 3 heteroatoms independently selected from N, S, or O; Each of m, n, q, k and s is independently selected from 0, 1, 2, 3 or 4.

2. 2. A compound according to claim 1, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, wherein: R 3 is H, halogen, -(CH 2 ) s -NR 4 R 5 , C1-4 alkyl, C1-4 alkoxyl, hydroxyl, oxo, CN, (CH 2 ) q -CONR 4 R 5 , -NR 4 R 5 , -NR 4 C (=NR 4 ) N.R. 4 R 5 , -S(O) 2 R 4 , C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, or C3-6 heterocycloalkyl, where C3-6 heterocycloalkyl contains 1, 2, or 3 heteroatoms independently selected from N, S, or O; C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C3-6 heterocycloalkyl contain one or more independently selected R 6 is optionally substituted with a substituent; Preferably, R 3 is H, halogen, -(CH 2 ) s -NR 4 R 5 , -CN,S(O) 2 R 4 , C1-4 alkyl, C1-4 alkoxyl, the -(CH 2 ) s -NR 4 R 5 , C1-4 alkyl, C1-4 alkoxyl is one or more independently selected R 6 It is optionally substituted with a substituent.

3. 3. A compound according to any one of claims 1 to 2, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, comprising: R 6 is H, halogen, hydroxy, oxo, CN, -(CH 2 ) k -NR 7 R 8 , -COR 7 , -NR 7 R 8 , -NR 7 C(=O)NR 7 R 8 , -S(O) 2 R 7 or R 6is selected from substituted or unsubstituted C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocycle, wherein said C5-6 heteroaryl and C3-10 heterocycle contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; Preferably, R 6 is H, halogen, hydroxy, oxo, CN, -(CH 2 )-N-(C1-4 alkyl) 2 , -(CH 2 )-NH2, -N-(C1-4 alkyl) 2 , -NH 2 , —CO—N—(C1-4 alkyl) 2 , —CO—NH 2 , -S(O) 2 -C1-4 alkyl, C1-4 alkyl-OH, C1-4 alkyl, C1-4 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C5-6 aryl, C5-6 heteroaryl, C3-10 heterocycle, wherein said C5-6 heteroaryl and C3-10 heterocycle contain 1, 2 or 3 heteroatoms independently selected from N, S, or O; More preferably, R 6 is halogen, oxo, -OH, -NH 2 , -N(CH 3 ) 2 , —C1-4 alkylOH, —C1-4 alkyl-NH—CH 3 , —NH—C1-4 alkyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxyl, C5-6 aryl, C5-6 heteroaryl, C3-6 heterocyclyl, guanidine.

4. 10. A compound according to claim 1, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, wherein: R 1 and R 2 are each independently selected from halogen, CN, —C1-6 alkyl, or —C1-4 haloalkyl; Q is -NH- or -(CH 2 ) m is an —O— bond; Ring A is a C5-6 aryl or C5-6 heteroaryl ring, said C5-6 heteroaryl ring containing 1, 2, or 3 heteroatoms independently selected from N, S, or O; Or Ring A is a C8-10 fused bicyclic ring; R 3 is H, halogen, -(CH 2 )s-NR 4 R 5 , -C1-4 alkyl, -C1-4 alkoxyl, and the -(CH 2 ) s -NR 4 R 5 , -C1-4 alkyl, -C1-4 alkoxyl is optionally substituted with halogen, -C1-4 alkyl, -C1-4 haloalkyl, -C1-4 alkoxyl, -C5-6 heteroaryl, -C5-6 aryl, carboxyl, amino, hydroxyl, guanidine, one or more independently selected substituents; R 4 and R 5 are each independently selected from H, -C1-4 alkyl, -C3-6 cycloalkyl, and -C3-6 heterocyclyl, and the -C1-4 alkyl, -C3-6 cycloalkyl, and -C3-6 heterocyclyl are halogen, -OH, N(CH 3 ) 2 , optionally substituted with -C1-4 alkyl, -C1-4 haloalkyl, -C3-6 heterocyclyl, -NH-C1-4 alkyl; Or R 4 and R 5 and the atoms belonging to the 4- to 6-membered heterocyclic ring, -OH, -N(CH 3 ) 2 , -NH 2 , oxo, halogen, -C1-4 alkyl, -C1-4 alkoxyl, -C1-4 alkylOH, -C1-4 alkylNH-CH 3 optionally substituted with one or more substituents independently selected from m, n, and s are each independently selected from 0, 1, 2, 3, or 4.

5. The compound according to any one of claims 1 to 4, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, wherein Q is selected from -NH-, or -CH2-O- bond.

6. 6. The compound of claim 1, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein ring A is is selected from Preferably, ring A is is selected from More preferably, ring A is is selected from.

7. 5. The compound of any one of claims 1 to 4, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein the compound has the structure of formula (II): [Case 2] or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein Ring B is a C5-6 cycloalkyl or a C5-6 heterocycloalkyl; Or the compound, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein the compound has the structure of formula (III): [C3] wherein Ring C is phenyl or heteroaryl, the heteroaryl containing 1, 2 or 3 N atoms; Or the compound, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein the compound has the structure of formula (IV): [C4] wherein Ring D is a C5-6 aryl, C5-6 heteroaryl, or C5-6 heterocycloalkyl, said C5-6 heteroaryl and C5-6 heterocycloalkyl containing 1, 2, or 3 heteroatoms independently selected from N, S, or O; or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein the compound has the structure of formula (V): [C5] Or the compound, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein the compound has the structure of formula (VI): [C6]

8. A compound according to any one of claims 1 to 7, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, wherein R 1 is F, C l , -CH 3 , —CN or —O—CH 3 is selected from Preferably, R 1 Ha-CH 3 , F, or —O—CH 3 is selected from.

9. A compound according to any one of claims 1 to 8, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, wherein R 2 Ha-CH 3 , F, Cl, or Br; Preferably, R 2 Ha-CH 3 It is.

10. A compound according to any one of claims 1 to 9, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, wherein R 3 teeth H, F, Cl, -CH 3 , -CF 3 , -O-CF 3 , -O-CHF 2 , —O—CH 3 , -CN, -NH 2 , is selected from.

11. The compound according to any one of claims 1 to 10, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein s is 1.

12. 12. The compound of any one of claims 1 to 11, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein m is 1.

13. 10. The compound of claim 1, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein the compound is 1) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 2) (2'S)-(((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(6-(difluoromethoxy)benzo[d]oxazole-2,5-diyl))bis(methylene))di-L-proline; 3) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((S)-2-(methoxycarbonyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 4) ((2-(2'-cyano-3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 5) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 6) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2'-fluoro-2-methyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 7) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((2-hydroxyethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 8) ((2-(3'-(5-(azetidin-1-ylmethyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 9) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-fluoroazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 10) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-fluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 11) ((2-(3'-(5-(((S)-2-carbamoylpyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 12) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 13) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(morpholinomethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 14) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-hydroxypyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 15) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((methylamino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 16) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((dimethylamino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 17) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((2-hydroxyethyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 18) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((3R,4R)-3,4-difluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 19) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 20) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-hydroxyazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 21) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((ethylamino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 22) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((3,3,3-trifluoro-2-hydroxypropyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 23) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3,4-dimethylpiperazin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 24) ((2-(3'-(5-(aminomethyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 25) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 26) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((((1R,2S)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 27) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((((1S,2R)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 28) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((oxetan-3-ylamino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 29) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((((R)-tetrahydrofuran-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 30) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((methyl(((R)-tetrahydrofuran-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 31) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((S)-2-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 32) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((2-(methylsulfonyl)ethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 33) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-(dimethylamino)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 34) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 35) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((R)-2-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 36) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 37) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2-hydroxy-2-methylazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 38) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2-methylpyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 39) ((2-(3'-(5-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 40) ((2-(3'-(5-(2-amino-2-methylazetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 41) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-(methylsulfonyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 42) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((R)-2-ethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 43) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-methoxyazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 44) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-hydroxy-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 45) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-((methylamino)methyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 46) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-oxoazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 47) ((2-(3'-(5-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 48) ((2-(3'-(5-((2-azaspiro[3.3]heptan-2-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 49) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 50) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 51) ((2-(3'-(5-((2,7-diazaspiro[3.5]nonan-2-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 52) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((3-(propylamino)propyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 53) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((methyl(3-(propylamino)propyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 54) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2,2-dioxido-2-thia-6-azaspiro[3.3]heptan-6-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 55) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 56) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 57) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((((1R,2R)-2-hydroxycyclopentyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 58) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((3-((2-hydroxyethyl)amino)propyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 59) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 60) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 61) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 62) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2,2-dimethylpyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 63) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((S)-2-(methoxymethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 64) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(((((S)-tetrahydrofuran-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 65) ((2-(2'-cyano-3'-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 66) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 67) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3,3-dimethylpyrrolidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 68) ((2-(3'-(5-((3-(diethylamino)azetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 69) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-(2-hydroxypropan-2-yl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 70) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((2,5-dihydro-1H-pyrrol-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 71) ((2-(3'-(5-((2-azabicyclo[2.1.1]hexan-2-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 72) ((2-(3'-(5-(((1s,4s)-7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 73) ((2-(3'-(5-((((3,3-difluoro-1-(hydroxymethyl)cyclobutyl)methyl)amino)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 74) ((2-(3'-(5-((5-azaspiro[2.3]hexan-5-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 75) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-oxo-6-azabicyclo[3.2.1]octan-6-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 76) ((2-(3'-(5-((1,1-difluoro-5-azaspiro[2.3]hexan-5-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 77) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-(hydroxymethyl)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 78) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-(hydroxymethyl)-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 79) ((2-(3'-(5-((3-cyano-3-methylazetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 80) ((2-(3'-(5-((3-cyanoazetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 81) ((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3-methyleneazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 82) ((2-(3'-(5-((3-(cyanomethylene)azetidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 83) ((2-(2,2'-dicyano-3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 84) ((6-(difluoromethoxy)-2-(3'-(5-((3,4-dimethylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 85) (R)-1-((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 86) (S)-1-((6-(difluoromethoxy)-2-(3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 87) ((2-(2'-cyano-3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 88) ((6-(difluoromethoxy)-2-(2,2'-dimethyl-3'-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 89) ((2-(3'-(5-((2-azabicyclo[2.1.1]hexan-2-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 90) ((6-(difluoromethoxy)-2-(2,2'-dimethyl-3'-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 91) (3R)-1-((6-(difluoromethoxy)-2-(2,2'-dimethyl-3'-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 92) (3S)-1-((6-(difluoromethoxy)-2-(2,2'-dimethyl-3'-(5-((3-methylpyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 93) ((6-(difluoromethoxy)-2-(3'-(5-((3,3-dimethylazetidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 94) ((2-(3'-(5-(azetidin-1-ylmethyl)-7-methylbenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 95) ((6-(difluoromethoxy)-2-(3'-(7-fluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 96) ((6-(difluoromethoxy)-2-(3'-(5-(ethylamino)methyl)-6-fluorobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 97) ((2-(3'-(6-chloro-5-((ethylamino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 98) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 99) ((6-(difluoromethoxy)-2-(3'-(5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 100) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 101) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-6-(trifluoromethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 102) ((2-(3'-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 103) ((2-(3'-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 104) ((6-(difluoromethoxy)-2-(3'-(5-((2-hydroxy-2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 105) ((6-(difluoromethoxy)-2-(3'-(5-((2-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 106) ((2-(3'-(5-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 107) ((2-(3'-(5-((1-azaspiro[3.3]heptan-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 108) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 109) ((6-(difluoromethoxy)-2-(3'-(6-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 110) ((2-(2'-chloro-3'-(6-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 111) ((2-(2'-chloro-3'-(6-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 112) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)oxazolo[5,4-b]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 113) ((6-(difluoromethoxy)-2-(3'-(6-((3,3-dimethylazetidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 114) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(((R)-3-methylpyrrolidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 115) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)oxazolo[5,4-b]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 116) ((6-(difluoromethoxy)-2-(3'-(6-((3-(dimethylamino)azetidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 117) ((2-(3'-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2'-methoxy-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 118) ((2-(2'-cyano-3'-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 119) ((2-(3'-(6-((6-cyanopyridin-3-yl)methoxy)-5-(((2-hydroxyethyl)methyl)amino)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 120) ((2-(3'-(6-((5-cyanopyridin-3-yl)methoxy)-5-(((2-hydroxyethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 121) ((6-(difluoromethoxy)-2-(3'-(5-(((2-hydroxyethyl)amino)methyl)-6-((5-(methylsulfonyl)pyridin-3-yl)methoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 122) ((6-(difluoromethoxy)-2-(3'-(5-((ethylamino)methyl)-6-((5-(methylsulfonyl)pyridin-3-yl)methoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 123) ((6-(difluoromethoxy)-2-(3'-(5-((dimethylamino)methyl)-6-((5-(methylsulfonyl)pyridin-3-yl)methoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 124) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(methylamino)methyl)-6-((3-(methylsulfonyl)benzyl)oxy)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 125) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((methylamino)methyl)-6-((4-(methylsulfonyl)benzyl)oxy)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 126) ((6-(difluoromethoxy)-2-(3'-(5-((dimethylamino)methyl)-6-((4-(methylsulfonyl)benzyl)oxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 127) ((2-(3'-(7-cyano-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 128) ((2-(2-cyano-3'-(6-(difluoromethoxy)-5-((3,3-dimethylazetidin-1-yl)methyl))benzo[d]oxazol-2-yl)-2'-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 129) ((2-(3'-(7-cyano-5-((3-(hydroxymethyl)-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 130) ((2-(3'-(7-cyano-5-(((S)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 131) ((2-(3'-(7-cyano-5-(((R)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 132) ((2-(3'-(7-cyano-5-(((R)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 133) ((2-(3'-(7-cyano-5-(((3-methyloxetan-3-yl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 134) ((2-(3'-(7-cyano-5-((3-(dimethylamino)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 135) ((2-(3'-(7-cyano-5-((2-(2-hydroxyethyl)piperidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 136) ((2-(3'-(7-cyano-5-(((cyanomethyl)(methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 137) ((2-(3'-(7-cyano-5-((3-(hydroxymethyl)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 138) ((2-(3'-(7-cyano-5-(((2-hydroxy-2-methylpropyl)amino)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 139) ((2-(3'-(7-cyano-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 140) ((2-(3'-(7-cyano-5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 141) ((2-(3'-(7-cyano-5-((ethyl(2-hydroxyethyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 142) ((2-(3'-(7-cyano-5-((3-cyanopyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 143) ((2-(3'-(7-cyano-5-((3-cyanopyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 144) ((2-(3'-(7-cyano-5-((3-ethynyl-3-hydroxyazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 145) ((2-(3'-(7-cyano-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 146) ((2-(3′-(7-cyano-5-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 147) ((2-(3'-(5-((bis(1-hydroxypropan-2-yl)amino)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 148) ((2-(3'-(7-cyano-5-((3-morpholinoazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 149) ((2-(3'-(7-cyano-5-((3-(methyl(oxetan-3-yl)amino)azetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 150) ((2-(3'-(7-cyano-5-((3-hydroxy-3-methyl-[1,3'-biazetidin]-1'-yl)methyl))benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 151) ((2-(3′-(7-cyano-5-((6-oxo-2,5-diazaspiro[3.4]octan-2-yl)methyl)benzo[d]oxazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 152) ((2-(3'-(7-cyano-5-((3-((dimethylamino)methyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 153) ((2-(3'-(7-cyano-5-((1,1-difluoro-5-azaspiro[2.4]heptan-5-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 154) ((2-(3'-(7-cyano-5-(((R)-3-(hydroxymethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 155) ((2-(3'-(7-cyano-5-(((3-hydroxycyclobutyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 156) ((2-(3'-(5-((3-amino-4-methylpyrrolidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 157) ((2-(3'-(5-(((azetidin-3-ylmethyl)amino)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 158) ((2-(3'-(7-cyano-5-((3-(dimethylamino)-4-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 159) ((2-(3'-(7-cyano-5-((3-(dimethylamino)methyl)-3-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 160) ((2-(3'-(7-cyano-5-((((1-methyl-1H-imidazol-4-yl)methyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 161) ((2-(3'-(5-((3-(aminomethyl)-3-methylazetidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 162) ((2-(3'-(7-cyano-5-((3-fluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 163) ((2-(3'-(7-cyano-5-((3-fluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 164) ((2-(3'-(7-cyano-5-((3,4-difluoropyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 165) ((2-(3'-(7-cyano-5-(((R)-3-cyanopyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 166) ((6-(difluoromethoxy)-2-(3'-(5-((3-fluoropyrrolidin-1-yl)methyl)-7-(trifluoromethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 167) ((2-(3'-(7-cyano-5-((3-fluoro-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 168) ((2-(3'-(7-cyano-5-(((R)-3-(fluoromethyl)pyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 169) (R)-1-((2-(3'-(7-cyano-5-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 170) ((6-(difluoromethoxy)-2-(3'-(6-((3,3-dimethylazetidin-1-yl)methyl)oxazolo[5,4-b]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 171) (S)-1-((8-((3'-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)amino)-1,7-naphthyridine-3-yl)methyl)-2-methylpyrrolidine-2-carboxylic acid; 172) ((2-(3'-((3-(((carboxymethyl)amino)methyl)-1,7-naphthyridine-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 173) (S)-1-((8-((3'-(5-(((S)-2-carboxypyrrolidin-1-yl)methyl)-6-(difluoromethoxy)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)amino)-1,7-naphthyridin-3-yl)methyl)piperidine-2-carboxylic acid; 174) ((6-(difluoromethoxy)-2-(3'-((3-((3-fluoropyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 175) ((6-(difluoromethoxy)-2-(3'-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 176) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((3-(morpholinomethyl)-1,7-naphthyridin-8-yl)amino)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 177) ((2-(3'-((3-(azetidin-1-ylmethyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 178) ((6-(difluoromethoxy)-2-(3'-((3-((3-hydroxyazetidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 179) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((3-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-1,7-naphthyridin-8-yl)amino)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 180) (3S)-1-((6-(difluoromethoxy)-2-(3'-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 181) (3R)-1-((6-(difluoromethoxy)-2-(3'-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 182) ((6-(difluoromethoxy)-2-(3'-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 183) ((5-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)amino)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-6-yl)methyl)-L-proline; 184) ((2-(3'-(5-(carboxymethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 185) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(2-(methylsulfonyl)ethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 186) ((2-(3'-(5-(1-carboxyethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 187) ((2-(3'-(5-(2-carboxyethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 188) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 189) ((6-(difluoromethoxy)-2-(3'-(5-(2-hydroxyethyl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 190) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 191) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 192) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(oxetan-2-ylmethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 193) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 194) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 195) ((2-(3'-(5-(cyanomethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 196) ((2-(3'-(5-(2-amino-2-oxoethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 197) ((6-(difluoromethoxy)-2-(3'-(5-(ethylsulfonyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 198) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 199) ((6-(difluoromethoxy)-2-(3'-(5-(3-hydroxypropyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 200) ((6-(difluoromethoxy)-2-(3'-(5-(3-fluoropropyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 201) ((2-(3'-(5-(2,2-difluoroethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 202) ((6-(difluoromethoxy)-2-(3'-(5,6-dihydro-4H-pyrrolo[3,4-d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 203) ((6-(difluoromethoxy)-2-(3'-(6,7-dihydro-4H-pyrano[3,4-d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 204) ((6-(difluoromethoxy)-2-(3'-(5,6-dihydro-4H-cyclopenta[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 205) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrobenzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 206) ((6-(difluoromethoxy)-2-(3'-(5-(2-hydroxyethyl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 207) 2-((2-(2'-cyano-2-methyl-3'-(4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)pyrrolidine-1-carboxylic acid; 208) ((2-(3'-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 209) ((2-(3'-((2-chloro-5-((5-(difluoromethoxy)pyridin-3-yl)methoxy)-4-((3-fluoropyrrolidin-1-yl)methyl)phenoxy)methyl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 210) ((2-(3'-((4-(((2-acetamidoethyl)amino)methyl)-2-chloro-5-((3-cyanobenzyl)oxy)phenoxy)methyl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 211) ((2-(3'-((4-(((S)-2-carboxypyrrolidin-1-yl)methyl)-2-chloro-5-((3-cyanobenzyl)oxy)phenoxy)methyl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 212) ((6-(difluoromethoxy)-2-(3'-(((4,6-dimethoxy-5-(pyrrolidin-1-ylmethyl)pyrimidin-2-yl)oxy)methyl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 213) ((6-(difluoromethoxy)-2-(3'-(((5-((3,3-dimethylazetidin-1-yl)methyl)-4,6-dimethoxypyrimidin-2-yl)oxy)methyl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 214) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-((5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyridin-2-yl)oxy)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 215) ((6-(difluoromethoxy)-2-(2′-fluoro-2-methyl-4″-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 216) ((6-(difluoromethoxy)-2-(3″-(difluoromethoxy)-2′-fluoro-2-methyl-4″-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 217) ((6-(difluoromethoxy)-2-(4″-(((2-hydroxyethyl)amino)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 218) ((6-(difluoromethoxy)-2-(2,2′,3″-trimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 219) ((2-(3″-chloro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 220) ((6-(difluoromethoxy)-2-(2″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 221) ((2-(2′-bromo-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 222) ((2-(2′-chloro-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 223) ((2-(2′-chloro-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 224) ((2-(2′-chloro-2″-fluoro-2-methyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-D-proline; 225) ((6-(difluoromethoxy)-2-(4″-guanidino-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 226) ((6-(difluoromethoxy)-2-(4″-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-2,2′-dimethyl-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 227) ((6-(difluoromethoxy)-2-(4″-((3-methoxypyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 228) ((6-(difluoromethoxy)-2-(4″-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 229) ((2-(3″-chloro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 230) ((6-(difluoromethoxy)-2-(2,2′,3″-trimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 231) ((2-(2″-chloro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 232) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-3″-(trifluoromethoxy)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 233) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-3″-(trifluoromethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 234) ((6-(difluoromethoxy)-2-(2,2′,3″,5″-tetramethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 235) ((6-(difluoromethoxy)-2-(3″-fluoro-5″-methoxy-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 236) ((2-(3″-carboxy-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 237) ((6-(difluoromethoxy)-2-(4″-((3,3-dimethylazetidin-1-yl)methyl)-3″-fluoro-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 238) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-((3-methylpyrrolidin-1-yl)methyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 239) ((6-(difluoromethoxy)-2-(3″-fluoro-4″-(((2-hydroxyethyl)amino)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 240) ((2-(3″-cyano-4″-(((S)-3-(hydroxymethyl)pyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 241) ((6-(difluoromethoxy)-2-(3″-fluoro-4″-(isoindolin-2-ylmethyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 242) ((6-(difluoromethoxy)-2-(4″-((3-fluoropyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 243) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 244) ((6-(difluoromethoxy)-2-(3″-(difluoromethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 245) ((2-(3″-cyano-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 246) ((6-(difluoromethoxy)-2-(3'-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 247) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 248) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-(((S)-3-phenylpyrrolidin-1-yl)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 249) ((6-(difluoromethoxy)-2-(3″-(4-fluorophenethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)proline; 250) ((2-(3″-(cyclopropylmethoxy)-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 251) ((2-(4″-(((R)-3-(1H-tetrazol-5-yl)pyrrolidin-1-yl)methyl)-3″-fluoro-2,2′-dimethyl-[1,1′:3′:1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 252) ((2-(4″-(((S)-3-((benzyloxy)methyl)pyrrolidin-1-yl)methyl)-3″-fluoro-2,2′-dimethyl-[1,1′:3′:1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)proline; 253) ((6-(difluoromethoxy)-2-(2″-fluoro-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 254) ((6-(difluoromethoxy)-2-(3″,5″-dimethoxy-2,2′-dimethyl-4″-(pyrrolidin-1-ylmethyl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline hydrochloride; 255) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-4″-(pyrrolidin-2-yl)-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 256) ((2-(4″-((S)-amino(carboxy)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 257) ((6-(difluoromethoxy)-2-(4″-(((S)-3-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)pyrrolidin-1-yl)methyl)-2,2′-dimethyl-[1,1′:3′,1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 258) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-((5-ureidoisoindolin-2-yl)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 259) (S)-1-((2-(3'-(7-cyano-5-(((S)-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; 260) ((6-(difluoromethoxy)-2-(3″-fluoro-2,2′-dimethyl-4″-((3-ureidopyrrolidin-1-yl)methyl)-[1,1′:3′:1″-terphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 261) ((2-(3'-(5-(((S)-3-chloropyrrolidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 262) ((6-(difluoromethoxy)-2-(3'-(4-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 263) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 264) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 265) ((6-(difluoromethoxy)-2-(3'-(5-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 266) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 267) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-oxo-5-(pyrrolidin-1-ylmethyl)-1,6-dihydropyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 268) ((6-(difluoromethoxy)-2-(2′-(difluoromethyl)-3′-(5-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2-methyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 269) ((6-(difluoromethoxy)-2-(3'-(5-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2'-(fluoromethyl)-2-methyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 270) ((6-(difluoromethoxy)-2-(3'-(2-fluoro-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 271) ((6-(difluoromethoxy)-2-(3'-(5-((3,3-dimethylazetidin-1-yl)methyl)-6-methoxypyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 272) ((6-(difluoromethoxy)-2-(3'-(6-methoxy-5-(((R)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 273) ((6-(difluoromethoxy)-2-(3'-(6-methoxy-5-(((S)-3-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 274) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-4-vinylpyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 275) ((6-(difluoromethoxy)-2-(3'-(5-((3-(difluoromethyl)pyrrolidin-1-yl)methyl)-6-methoxypyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)-methyl)-L-proline; 276) ((6-(difluoromethoxy)-2-(3'-(6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 277) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(((S)-2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 278) ((2-(3'-(5-(((1s,4s)-7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6-methoxypyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 279) ((6-(difluoromethoxy)-2-(3'-(6-methoxy-5-(((R)-2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 280) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)thiophen-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 281) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-(pyrrolidin-1-ylmethyl)pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 282) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 283) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 284) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)pyrazin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 285) ((6-(difluoromethoxy)-2-(3′-(6-methoxy-5-(pyrrolidin-1-ylmethyl)pyrazin-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 286) ((6-(difluoromethoxy)-2-(3'-(6-methoxy-5-(((R)-3-methylpyrrolidin-1-yl)methyl)pyrazin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 287) ((2-(2'-chloro-3'-(6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 288) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(1,2,3,4-tetrahydroisoquinolin-6-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 289) ((6-(difluoromethoxy)-2-(3'-(isoindolin-5-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 290) ((2-(3'-(2-(2-carboxyethyl)isoindolin-5-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 291) ((2-(3'-(2-(carboxymethyl)isoindolin-5-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 292) ((2-(3'-(2-(1-carboxyethyl)isoindolin-5-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 293) ((2-(3′-(2-amino-1H-benzo[d]imidazol-5-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 294) ((6-(difluoromethoxy)-2-(3'-(5-((3,3-dimethylpyrrolidin-1-yl)methyl)-6-methoxypyridin-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 295) ((2-(3′-(7-cyano-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 296) ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 297) ((6-(difluoromethoxy)-2-(3′-(6-fluoro-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 298) ((2-(3′-(6,7-difluoro-1-methyl-5-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 299) ((2-(3′-(6,7-difluoro-5-(pyrrolidin-1-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 300) ((2-(3'-(4,5-difluoro-6-(pyrrolidin-1-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 301) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-(pyrrolidin-1-ylmethyl)-7-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 302) ((2-(2'-chloro-3'-(5-(((2-hydroxyethyl)amino)methyl)picolinamido)-2-methyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 303) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamido)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 304) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-methyl-5-(pyrrolidin-1-ylmethyl)oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 305) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(6-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 306) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-(pyrrolidin-1-yl)piperidin-1-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 307) ((6-(difluoromethoxy)-2-(3'-(4-(((1-(hydroxymethyl)cyclopropyl)methyl)amino)piperidin-1-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 308) ((6-(difluoromethoxy)-2-(3'-(4-((3,3-dimethylazetidin-1-yl)methyl)piperidin-1-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 309) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(4-(pyrrolidin-1-ylmethyl)piperidin-1-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 310) ((6-(difluoromethoxy)-2-(3'-(5-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-D-proline; 311) ((6-(difluoromethoxy)-2-(3'-(5-((2,2-dimethylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 312) ((6-(difluoromethoxy)-2-(3'-(5-((3,3-dimethylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 313) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-((2-methylazetidin-1-yl)methyl)benzo[d]oxazol-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 314) ((6-(difluoromethoxy)-2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridin-2-yl)-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)-L-proline; 315) ((2-(3'-(5-((3-carbamoylpyrrolidin-1-yl)methyl)-7-cyanobenzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline; 316) ((2-(3'-(7-cyano-5-((3-cyano-3-methylpyrrolidin-1-yl)methyl)benzo[d]oxazol-2-yl)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)-6-(difluoromethoxy)benzo[d]oxazol-5-yl)methyl)-L-proline).

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt or stereoisomer thereof, and at least one pharma- ceutically acceptable carrier or excipient.

15. A pharmaceutical composition according to claim 14 or a use of a compound according to any one of claims 1 to 13 for the preparation of a medicament.

16. 16. The use according to claim 15 for the treatment or prevention of cancer.

17. 16. The use according to claim 15 in the treatment of colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.

18. The use according to claim 15, wherein the agent is an inhibitor of PD-1 / PD-L1 interaction.

19. 16. The use according to claim 15 for enhancing, stimulating and / or increasing an immune response in a patient.

Citation Information

Patent Citations

  • Heterocyclic compounds as immunomodulators

    WO2017087777A1

  • Benzooxazole derivatives as immunomodulators

    WO2018119266A1